Burcon NutraScience (BRCNF) 40-F 29 Jun 21 2021 FY Annual report (Canada) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Mar. 31, 2021shares
Document Information [Line Items]
Entity Registrant Name	Burcon NutraScience Corporation
Entity Central Index Key	0001158399
Document Type	40-F
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--03-31
Amendment Flag	false
Document Registration Statement	false
Entity Address, Address Line One	1946 West Broadway
Entity Address, State or Province	BC
Entity Address, City or Town	Vancouver
Entity Address, Postal Zip Code	V6J 1Z2
Entity Current Reporting Status	Yes
Entity File Number	0-0000
Document Annual Report	true
Annual Information Form	true
Audited Annual Financial Statements	true
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	Z4
Entity Common Stock, Shares Outstanding	108,431,377
Entity Ex Transition Period	false
Entity Emerging Growth Company	true
Security Exchange Name	NASDAQ
Trading Symbol	BRCN
Title of 12(b) Security	Common Shares
Local Phone Number	733-0896
City Area Code	604
ICFR Auditor Attestation Flag	false
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	DL Services Inc.
Entity Address, Address Line One	701 5
Entity Address, Address Line Two	Avenue Suite 6100
Entity Address, State or Province	WA
Entity Address, City or Town	Seattle
Entity Address, Postal Zip Code	98104
Local Phone Number	903-8800
City Area Code	206

Consolidated Balance Sheets

Consolidated Balance Sheets - CAD ($)	Mar. 31, 2021	Mar. 31, 2020
Current assets
Cash and cash equivalents	$ 13,972,659	$ 15,030,988
Amounts receivable	338,715	332,248
Inventory	132,473	132,142
Prepaid expenses	154,757	289,278
Total current assets	14,598,604	15,784,656
Property and equipment	1,005,760	470,504
Deferred development costs - net of accumulated amortization of $nil (2020 - $nil)	4,463,748	1,554,584
Investment in and loan to Merit Functional Foods Corporation	16,401,703	12,204,538
Goodwill	1,254,930	1,254,930
Total assets	37,724,745	31,269,212
Current liabilities
Accounts payable and accrued liabilities	1,418,049	1,067,251
Lease liability	28,431	0
Deferred revenue	0	275,578
Accrued interest	0	249,310
Total current liabilities	1,446,480	1,592,139
Lease liability	5,266	0
Convertible debentures	0	6,731,350
Total liabilities	1,451,746	8,323,489
SHAREHOLDERS’ EQUITY
Capital stock	114,106,836	98,046,103
Contributed surplus	14,058,654	9,030,861
Options	6,490,537	9,673,821
Warrants	594,621	1,792,168
Convertible debentures	0	2,762,927
Deficit	(98,977,649)	(98,360,157)
Total equity	36,272,999	22,945,723
Total equity and liabilities	$ 37,724,745	$ 31,269,212

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - CAD ($)	Mar. 31, 2021	Mar. 31, 2020
Statement of financial position [abstract]
Accumulated amortization on deferred development costs

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
REVENUE
Research income	$ 250,000	$ 0
Royalty income	8,646	31,134
Total revenue	258,646	31,134
EXPENSES
Research and development	414,005	721,851
Intellectual property	785,957	846,137
General and administrative	3,654,142	2,186,273
EXPENSES	4,854,104	3,754,261
LOSS FROM OPERATIONS	(4,595,458)	(3,723,127)
INTEREST AND OTHER INCOME	446,765	247,918
MANAGEMENT FEE INCOME	342,469	364,210
GAIN ON DILUTION OF INVESTMENT IN MERIT FUNCTIONAL FOODS CORPORATION	6,384,942	0
SHARE OF LOSS IN MERIT FUNCTIONAL FOODS CORPORATION	(2,421,459)	(939,806)
INTEREST AND OTHER EXPENSE	(770,404)	(589,277)
FOREIGN EXCHANGE (LOSS) GAIN	(4,347)	2,153
LOSS ON DISPOSAL OF EQUIPMENT	0	(949)
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITY	0	5,384
LOSS AND COMPREHENSIVE LOSS FOR THE YEAR	$ (617,492)	$ (4,633,494)
BASIC AND DILUTED LOSS PER SHARE	$ (0.01)	$ (0.06)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($)	Capital stock [Member]	Contributed surplus [Member]	Options [Member]	Warrants [Member]	Convertible debentures [Member]	Deficit [Member]	Total
Beginning Balance at Mar. 31, 2019	$ 73,361,133	$ 9,001,467	$ 9,184,852	$ 199,117	$ 0	$ (93,726,663)	$ (1,980,094)
Beginning Balance (shares) at Mar. 31, 2019	43,941,536
Loss and comprehensive loss for the year						(4,633,494)	(4,633,494)
Shares issued	$ 25,149,059						25,149,059
Shares issued (shares)	51,503,003
Options exercised	$ 118,350		(47,279)				71,071
Options exercised (shares)	173,000
Options cancelled		29,394	(29,394)
Warrants issued				2,030,058			2,030,058
Warrants exercised	$ 816,482			(284,538)			531,944
Warrants exercised (shares)	1,182,099
Warrant adjustment				85,421			85,421
Share issue costs	$ (1,398,921)						(1,398,921)
Warrant issue costs				(237,890)			(237,890)
Convertible debentures					2,762,927		2,762,927
Stock-based compensation expense			565,642				565,642
Ending Balance at Mar. 31, 2020	$ 98,046,103	9,030,861	9,673,821	1,792,168	2,762,927	(98,360,157)	22,945,723
Ending Balance (shares) at Mar. 31, 2020	96,799,638
Loss and comprehensive loss for the year						(617,492)	(617,492)
Conversion of convertible debentures	$ 9,809,012				(2,762,927)		(7,046,085)
Conversion of convertible debentures (shares)	9,047,601
Options exercised	$ 72,735		(33,635)				39,100
Options exercised (shares)	90,884
Options expired		5,027,793	(5,027,793)
Warrants exercised	$ 6,183,270			(1,196,762)			4,986,508
Warrants exercised (shares)	2,493,254
Share issue costs	$ (4,284)						(4,284)
Warrant issue costs				(785)			(785)
Stock-based compensation expense			1,878,144				1,878,144
Ending Balance at Mar. 31, 2021	$ 114,106,836	$ 14,058,654	$ 6,490,537	$ 594,621	$ 0	$ (98,977,649)	$ 36,272,999
Ending Balance (shares) at Mar. 31, 2021	108,431,377

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Loss for the year	$ (617,492)	$ (4,633,494)
Items not affecting cash
Amortization of property and equipment	123,234	37,290
Unrealized foreign exchange loss (gain)	4,474	(1,798)
Interest accretion	(307,875)	(144,343)
Finance income	(6,144)	0
Interest and other expense	770,403	589,277
Gain on dilution of investment in Merit Functional Foods Corporation	(6,384,942)	0
Change in fair value of derivative liability	0	(5,384)
Share of loss in Merit Functional Foods Corporation	2,421,459	939,806
Loss on disposal of equipment	0	949
Warrant adjustment	0	85,420
Stock-based compensation expense	1,646,615	514,983
Cash flows from (used in) operations	(2,350,268)	(2,617,294)
Changes in non-cash working capital items
Amounts receivable	(6,467)	(205,643)
Inventory	(331)	(132,142)
Prepaid expenses	137,279	18,719
Accounts payable and accrued liabilities	190,487	39,806
Deferred revenue	(275,578)	275,578
Cash used in operating activities	(2,304,878)	(2,620,976)
Interest received	(155,973)	(79,812)
Interest paid	(572,097)	(672,195)
Cash flows from (used in) operating activities	(3,032,948)	(3,372,983)
CASH FLOWS FROM INVESTING ACTIVITIES
Interest received	155,973	79,812
Investment in Merit Functional Foods Corporation	0	(13,000,000)
Development costs deferred	(1,978,217)	(1,467,076)
Acquisition of property and equipment	(894,529)	(101,187)
Cash flows from (used in) investing activities	(2,716,773)	(14,488,451)
CASH FLOWS FROM FINANCING ACTIVITIES
Issue of capital stock	5,025,608	25,752,074
Issue of warrants	0	1,780,752
Issue of convertible debentures	0	9,500,000
Issue costs	(239,589)	(1,381,417)
Lease liability	(90,153)	0
Short-term loan	0	250,000
Repayment of convertible note	0	(2,000,000)
Repayment of short-term loan	0	(1,500,000)
Cash flows from (used in) financing activities	4,695,866	32,401,409
FOREIGN EXCHANGE (LOSS) GAIN ON CASH AND CASH EQUIVALENTS	(4,474)	1,798
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(1,058,329)	14,541,773
CASH AND CASH EQUIVALENTS – BEGINNING OF YEAR	15,030,988	489,215
CASH AND CASH EQUIVALENTS – END OF YEAR	$ 13,972,659	$ 15,030,988

Nature of operations

Nature of operations	12 Months Ended
	Mar. 31, 2021
Disclosure Of Nature Of Operations [Abstract]
Nature of operations [Text Block]	1. Nature of operations Burcon NutraScience Corporation ("Burcon" or the "Company") is an incorporated entity headquartered in Vancouver, British Columbia, Canada. Burcon is a research and development company that has developed plant protein extraction and purification technology in the field of functional, renewable plant proteins. The Company has an extensive portfolio of composition, application and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. a) Burcon has developed novel pea proteins that it has branded Peazazz ® ® ® ® ® In May 2019, Burcon and two other entities formed Merit Functional Foods Corporation ("Merit Foods"). Merit Foods has completed the construction of a 94,000 square foot protein commercial production facility in Manitoba, Canada to produce, under license, Burcon's pea and canola protein b) ® Burcon had a license and production agreement (the "Soy Agreement") with Archer Daniels Midland Company ("ADM") to license its CLARISOY ® ®

Significant accounting policies

Significant accounting policies	12 Months Ended
	Mar. 31, 2021
Disclosure Of Significant Accounting Policies [Abstract]
Significant accounting policies [Text Block]	2. Significant accounting policies Basis of presentation These consolidated financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”). The Company has consistently applied the same accounting policies throughout all periods presented. Certain comparatives have been restated to conform with this year's presentation. The board of directors approved these consolidated financial statements on June 24, 2021. Principles of consolidation These consolidated financial statements include the accounts of the Company and its subsidiaries, Burcon NutraScience (MB) Corp. ("Burcon-MB") and Burcon NutraScience Holdings Corp. ("Burcon Holdings"). A subsidiary is an entity in which the Company has control, directly or indirectly. Under IFRS 10, an investor controls an investee if and only if the investor has power over the investee, exposure, or rights, to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor's returns. All material intercompany transactions and balances have been eliminated on consolidation. Details of the Company's subsidiaries at March 31, 2021 are as follows: Place of incorporation Interest % Principal activity Burcon NutraScience (MB) Corp. Manitoba, Canada 100 Research and development Burcon NutraScience Holdings Corp. Canadian federally incorporated 100 Investment holding Investment in Associates An associate is an entity over which the Company has significant influence. Significant influence is the power to participate in the financial and operating policy of the investee without the power to control or jointly control those policies. The results and assets and liabilities of associates are incorporated in these consolidated financial statements using the equity method of accounting. Under the equity method of accounting, investments are recorded at historical cost as an asset and adjusted for dividends received, capital contributions, other transactions that result in changes in ownership interest held by the Company, and the Company's share of Merit's earnings or losses, which is recorded as a component of Loss and Comprehensive Loss for the year. When the Company's share of losses of an associate exceeds the Company's interest in the associate, which includes any long-term interests that, in substance, form part of the Company's net investment in the associate, the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate. Management considers whether there are any indicators of impairment to determine whether it is necessary to recognize any impairment loss with respect to the Company's investment in an associate. When such indicators of impairment exist, the carrying amount of the investment is tested for impairment by comparing the recoverable amount with its carrying amount of the investment. Any reversal of that impairment loss is recognized to the extent that the recoverable amount of the investment subsequently increases. Revenue recognition The Company recognizes revenue when the amount of revenue can be reliably measured, and it is probable that future economic benefits will flow to the Company. The Company may earn revenues from licensing agreements under which third parties are granted rights to use the Company's technologies. If the substantive rights to the technologies are retained by the Company, or the Company has remaining performance obligations under the licensing agreements, and as such not all of the risks and rewards have been transferred to the licensee, the Company recognizes amounts received or receivable as royalties when earned on an accrual basis. At the point when all of the risks and rewards associated with the use of the technologies have, in substance, been relinquished under the licensing agreements, the Company recognizes the fair value of future payments expected to be received as proceeds from the sale of the technologies in the consolidated statements of operations and comprehensive loss, once the expected future payments can be reliably measured. Upfront payments and similar non-refundable payments received under these agreements are initially recognized as deferred revenue. Subsequently, if the Company recognizes royalty revenue, the amounts deferred are recognized as revenue on a straight-line basis over the estimated period royalties are expected to be earned commencing in the period royalties are first recognized as revenue. Otherwise, the deferred amounts are recognized as sale proceeds at the date of sale of the technologies. License agreements may consist of multiple elements and provide for varying consideration terms, such as upfront payments and milestone or similar payments. Revenue arrangements with multiple elements are reviewed in order to determine whether the multiple elements can be divided into separate units of accounting. If separable, the consideration received is allocated among the separate units of accounting based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units. Otherwise, the applicable revenue recognition criteria are applied to the revenue arrangement as a single unit. Government assistance The Company carries out research and development in Canada that is eligible for Scientific Research and Experimental Development ("SR&ED") Investment Tax Credits ("ITC") at both the federal and provincial level. The Company has recognized the refundable portion of ITC at the provincial level but has not recognized the benefits of ITC at the federal level because realization of these benefits is not probable at this time. The Company's determination of ITC involves uncertainty with respect to management's interpretation of complex tax regulations. The ITC claims are subject to review and acceptance by the Canada Revenue Agency prior to collection. Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Company with no future related costs are recognized in the statement of profit or loss in the period in which they become receivable. Accounting estimates and judgments The preparation of consolidated financial statements in accordance with IFRS requires management to apply judgment when making estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, the reported amount of revenue and expenses during the reporting period, and disclosures made in the accompanying notes to the consolidated financial statements. Actual results may differ from those estimates. The significant areas where management's judgment is applied are in determining the fair value of stock-based compensation (see note 9 for assumptions used by management), whether all criteria for deferring development costs are met, the point at which amortization of development costs commences, the expense allocation to deferred development costs and the recoverable amounts of investment in associates, expected credit losses on loans receivable, goodwill, and the discount rate used to fair value the loans receivable from Merit Foods following their modification (note 5). Cash and cash equivalents Cash and cash equivalents consist of cash on deposit with banks and highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less. Financial instruments Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial assets and liabilities are offset and the net amount is reported in the consolidated balance sheets when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously. At initial recognition, the Company classifies its financial instruments in one of the following categories: amortized cost, fair value through profit or loss, and fair value through other comprehensive income. Derivatives are recognized initially and subsequently at fair value. Transaction costs are expensed in the consolidated statements of operations and comprehensive loss. Gains and losses arising from changes in fair value are presented in the consolidated statements of operations and comprehensive loss, through profit or loss, in the period in which they arise. Financial assets carried at amortized cost, which include loans and receivables initially recognized at the amount expected to be received, less a provision for the expected credit loss. Subsequently, financial assets carried at amortized cost are measured at amortized cost using the effective interest method less a provision for the expected credit loss. The Company classifies its cash and cash equivalents and amounts receivable as financial assets carried at amortized cost. Other financial liabilities are initially recognized at the amount required to be paid, less, when material, a discount to reduce the payables to fair value. Subsequently, other financial liabilities are measured at amortized cost using the effective interest method. At each reporting date, the Company assesses whether there is objective evidence that a financial asset is impaired. If such evidence exists, the Company recognizes an impairment loss, as follows: Financial assets carried at amortized cost: the impairment loss is the difference between the carrying value of the asset and the amortized cost of the financial asset, less the expected credit loss. The carrying amount of the asset is reduced by this amount which is recognized in the consolidated statements of operations and comprehensive loss, through profit or loss. Impairment losses on financial assets carried at amortized cost are reversed in subsequent periods if the amount of the expected credit loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized. Transaction costs of an equity transaction are accounted for as a deduction from equity to the extent that they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided. Qualifying transaction costs incurred prior to the Company's year-end in anticipation of an issuance of equity instruments subsequent to the Company's year-end are deferred on the consolidated balance sheets until the equity instruments are issued. Property and equipment Property and equipment are recorded at cost less accumulated amortization. The Company provides for amortization at the following annual rates: Equipment 20% declining balance Computer equipment 30% declining balance Leasehold improvements Straight-line over lease term Right-of-use assets Straight-line over lease term Inventories Inventories are recorded at the lower of cost and net realizable value. Impairment of long-lived assets The Company tests property and equipment for impairment whenever events or circumstances indicate that the carrying value of an asset or group of assets may not be recoverable. Intangible assets that are not being amortized are tested annually for impairment and also if the Company identifies indicators of impairment. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash-generating units). The evaluation is based on the higher of the asset's fair value less costs of disposal and its value in use, which is the present value of future cash flows expected to be derived from the asset in its current state. An impairment loss is recognized in the period it is determined to the extent that the carrying value exceeds the higher of fair value less costs to sell and value in use of the asset or group of assets. Research and development costs Research costs are expensed in the year incurred. Development costs are also expensed in the year incurred unless the related process is clearly defined and the costs attributable thereto can be reliably measured; the technical feasibility of the process has been established so that it will be available for use or sale; management has indicated its intention to produce and market, or use, the process; an ability to use or sell the process exists; the process will generate probable future economic benefits; and adequate resources exist, or are expected to be available, to complete the development and to use or sell the process. On July 1, 2019, the Company commenced deferring development costs related to its pea and canola technologies. The deferred development costs will be amortized on a straight-line basis over their estimated useful lives commencing on the date the Company starts earning royalties. Goodwill Goodwill represents the excess at the date of acquisition of the cost of the acquired business over the fair values attributed to the underlying net tangible assets and the identifiable intangible assets. Goodwill is not amortized. On at least an annual basis, or when circumstances indicate the carrying value of goodwill may not be recoverable, the Company subjects goodwill to an impairment test. For impairment testing purposes, the carrying value of goodwill is allocated to the group of assets that realize the benefits of the acquisition. The impairment assessment is performed by comparing the carrying value of the group of assets, including the allocated carrying value of goodwill, to the higher of its fair value less costs to sell and its value in use, which is the present value of future cash flows expected to be derived from the group of assets in their current state. If the carrying amount of the group of assets exceeds the recoverable amount, an impairment loss is charged to operations in the period such impairment is identified, allocated first to reducing the carrying amount of the goodwill allocated to the group, and then to the other assets of the group. Income taxes The Company uses the balance sheet liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current year. Deferred income tax assets and liabilities are recognized in the current year for temporary differences between the tax and accounting bases of assets and liabilities as well as for the benefit of losses available to be carried forward to future years for tax purposes. Deferred income tax assets and liabilities are measured using substantively enacted tax rates and laws expected to apply in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets are recognized only to the extent they are considered probable to be realized. Stock-based compensation The Company accounts for stock-based compensation granted to employees using the fair value method calculated using the Black-Scholes option pricing model. Stock-based compensation granted to non-employees is measured at the fair value of the goods and services received unless the fair value cannot be measured reliably, in which case the amount is measured using the fair value of the options granted. For options granted to employees and those providing similar services, including officers and directors, the compensation cost is measured at the fair value of the equity instrument granted at the date of grant and is expensed to operations over the award's vesting period. When stock options are exercised, capital stock is credited by the sum of the consideration paid and by the related portion previously recorded in options. Additional information related to the stock option plan and the assumptions used in the Black-Scholes option pricing model are provided in note 9(c). Loss per share Basic loss per share is computed by dividing the net loss for the year available to common shareholders by the weighted average number of common shares outstanding during the year. The Company applies the treasury stock method to calculate diluted loss per share. Diluted loss per share excludes all dilutive potential common shares if their effect is anti-dilutive. Foreign currency translation a) Items included in the financial statements of each consolidated entity are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). These consolidated financial statements are presented in Canadian dollars, which is the Company's and its subsidiaries' functional currency. b) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the date of the transactions. Generally, foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in currencies other than an operation's functional currency are recognized in the consolidated statements of operations and comprehensive loss. Newly adopted accounting standards and amendments IFRS 16 - Leases Effective April 1, 2019, the Company adopted IFRS 16 - Leases, which requires, among other things, leases to recognize leases traditionally recorded as operating leases in the same manner as a financing lease. The Company applied IFRS 16 on a modified retrospective basis and it did not have a significant impact on the consolidated financial statements. Accounting standard and amendments issued and not yet adopted Amendments to IAS 1 - Classification of Liabilities as Current or Non-Current The amendment clarifies the classification requirements to determine if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing or recognition. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and is to be applied retrospectively, with earlier application permitted. The Company is still considering whether the new standard will have a significant impact on the consolidated financial statements.

Property and equipment

Property and equipment	12 Months Ended
	Mar. 31, 2021
Property, plant and equipment [abstract]
Property and equipment [Text Block]	3. Property and equipment Right-of-Use Computer Leasehold Equipment Assets Equipment improvements Total $ $ $ $ $ Cost at March 31, 2019 3,777,382 — 85,662 — 3,863,044 Additions 241,683 — 19,218 — 260,901 Disposals — — (3,764 ) — (3,764 ) Cost at March 31, 2020 4,019,065 — 101,116 — 4,120,181 Accumulated amortization at March 31, 2019 3,501,562 — 76,793 — 3,578,355 Amortization 68,916 — 5,221 — 74,137 Disposal — — (2,815 ) — (2,815 ) Accumulated amortization at March 31, 2020 3,570,478 — 79,199 — 3,649,677 Net book value at March 31, 2020 448,587 — 21,917 — 470,504 Right-of-Use Computer Leasehold Equipment Assets Equipment improvements Total $ $ $ $ $ Cost at March 31, 2020 4,019,065 — 101,116 — 4,120,181 Additions 628,493 68,549 22,224 88,644 807,910 Cost at March 31, 2021 4,647,558 68,549 123,340 88,644 4,928,091 Accumulated amortization at March 31, 2020 3,570,478 — 79,199 — 3,649,677 Amortization 157,593 46,056 9,909 59,096 272,654 Accumulated amortization at March 31, 2021 3,728,071 46,056 89,108 59,096 3,922,331 Net book value at March 31, 2021 919,487 22,493 34,232 29,548 1,005,760 Additions to property and equipment have been reduced by a cash grant received from the government of Manitoba of $50,000 (2020 - $nil).

Deferred development costs

Deferred development costs	12 Months Ended
	Mar. 31, 2021
Deferred Development Costs [Abstract]
Deferred development costs [Text Block]	4. Deferred development costs $ Cost at March 31, 2020 1,554,584 Additions 2,909,164 Cost at March 31, 2021 4,463,748 Amortization and impairment at March 31, 2021 — Net book value at March 31, 2021 4,463,748 Cost at March 31, 2019 — Additions 1,554,584 Cost at March 31, 2020 1,554,584 Amortization and impairment at March 31, 2020 — Net book value at March 31, 2020 1,554,584

Investment in and loan to Merit

Investment in and loan to Merit Functional Foods Corporation	12 Months Ended
	Mar. 31, 2021
Investment In And Loan To Shareholders [Abstract]
Investment in and loan to Merit Functional Foods Corporation [Text Block]	5. Investment in and loan to Merit Functional Foods Corporation On May 23, 2019, Burcon, through a new wholly-owned subsidiary incorporated on May 22, 2019, Burcon Holdings, entered into a shareholders' agreement (the "Shareholders' Agreement") with two other entities (the "Partners") to become shareholders of Merit Foods, to build and own a new commercial production facility (the "Flex Production Facility") in Manitoba, Canada to produce, sell, market and distribute Burcon's Peazazz ® ® ® ® ® ® ® On inception, Burcon Holdings held 40% of the issued and outstanding shares of Merit Foods, and the two other parties held 40% and 20%, respectively. Each shareholder made its respective capital loan advances in June, September, December 2019 and February 2020 by way of shareholder loans totalling $32.5 million (the "Merit Shareholder Loans"). On August 27, 2020, Bunge Limited ("Bunge") made an investment of $30 million into Merit Foods. In addition to purchasing equity directly from Merit Foods, Bunge purchased additional shares and debt from the other shareholders of Merit Foods. As a result of these transactions, Bunge became a 25% shareholder in Merit Foods and Burcon's ownership interest in Merit Foods decreased to 33.3%. As a result of the dilution in Burcon's ownership interest in Merit Foods, Burcon recorded a dilution gain of $6,384,942. Summary financial position for Merit Foods as at March 31, 2021 and 2020 As at March As at March 31, $ $ Current assets 16,125,384 5,828,739 Non-current assets 124,970,303 36,056,689 Current liabilities 9,303,585 11,369,931 Non-current liabilities 93,642,063 6,653,724 Summary financial results for Merit Foods Year ended Period ended 1 $ $ Total revenue 396,093 — Loss for the year/period (6,837,195 ) (2,349,515 ) ____________________________ 1 As at March 31, 2021, Burcon Holdings has made capital loan advances of $13.0 million to Merit Foods in the form of shareholder loans. Investment in $ Capital $ Loan receivable $ Total net $ At inception 1 — 11,000,000 11,000,001 Modification to loan terms 8,871,512 (8,871,512 ) — Capital loan advance — 1,613,002 386,998 2,000,000 Share of loss in Merit Foods — (939,806 ) — (939,806 ) Interest accretion — — 144,343 144,343 Net Investment in Merit Foods, March 31, 2020 1 9,544,708 2,659,829 12,204,538 Share of loss in Merit Foods — (2,421,459 ) — (2,421,459 ) Dilution gain of investment in Merit Foods — 6,384,942 — 6,384,942 Interest accretion — — 307,875 307,875 Expected credit loss provision — — (74,193 ) (74,193 ) Net Investment in Merit Foods, March 31, 2021 1 13,508,191 2,893,511 16,401,703 From inception to December 2019, the Merit Shareholder Loans were recorded as loan receivable. In December 2019, the terms of the Merit Shareholder Loans were finalized. The loans are non-interest bearing, unsecured, subordinated to Merit Foods' other secured and unsecured debts, have a term of 15 years, and may be repaid by Merit Foods, without penalty or bonus, on a pro-rata basis based on the proportionate share of each shareholder's loan outstanding in relation to the other shareholders of Merit Foods applied to the outstanding principal amounts. As a result, Burcon recalculated the fair value at that date, resulting in a reduction of the fair value of the loan receivable that was transferred to a capital contribution account. Notional interest is accruing on the loan receivable at 11% per annum, which is considered to be the market rate of interest. For the year ended March 31, 2021, the Company has recorded interest accretion of $307,875 (2020 - $144,343). An expected credit loss provision of $74,193 has been recognized in relation to the loan receivable and included in interest and other expense on the consolidated statement of operations and comprehensive loss. Burcon has a license agreement (the "License Agreement") with Merit Foods for an exclusive, royalty-bearing, worldwide license to use and exploit Burcon's Products. As part of the Bunge transaction, Bunge, Burcon and the Partners have amended the License Agreement (the "Amended License Agreement") and Burcon, Bunge and the Partners have also amended the Shareholders Agreement (the "Amended Shareholders Agreement"). Under the Amended License Agreement and Amended Shareholders Agreement, Burcon, Bunge and the Partners have agreed to certain contractual rights, including a right, but not an obligation, of Burcon, in certain circumstances, to participate in a sale of all but not less than all of its shares in Merit Foods, and that in certain circumstances, Merit Foods will have the right to buy out from Burcon the Amended License Agreement for $67.5 million, which represents the discounted future royalties over the life of the Amended License Agreement. Burcon has a services agreement (the "Services Agreement") with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. For the year ended March 31, 2021, included in management fee income is $334,760 (2020 - $350,014) for services provided and $524,321 (2020 - $114,766) for samples sold to Merit Foods, of which $66,709 was included in amounts receivable at March 31, 2021 (March 31, 2020 - $110,594). Merit Foods also provided certain technical and consulting services to Burcon. For the year ended March 31, 2021, Burcon recorded professional fee expense of $10,720 (2020 - $ nil In May 2020, Burcon announced that Merit Foods had secured a debt financing package of up to $85 million of capital from a syndicate of lenders including Export Development Canada ("EDC"), Farm Credit Canada ("FCC") and the Canadian Imperial Bank of Commerce. All of Merit Foods' shareholders, including Burcon Holdings, pledged their shares in Merit Foods as security under the loan facilities with EDC and FCC. In connection with the loan facilities from EDC, Merit Foods had to fulfill various obligations, including the establishment and maintenance of a cost overrun account in a prescribed amount in connection with the costs related to the construction of the Flex Production Facility. Of the prescribed amount, $6.5 million was permitted to be funded by way of a letter of credit ("LC"). To assist Merit Foods to fulfill this obligation, Burcon Holdings obtained the LC from HSBC Bank Canada ("HSBC") in April 2020, which was secured by a term deposit with HSBC in the same amount. As part of the investment by Bunge into Merit Foods, the LC was released on August 28, 2020. In connection with the LC, Burcon Holdings entered into a short-term loan agreement (the "Merit Loan Agreement") with Merit Foods in the amount of $6.5 million (the "Merit Loan"). The Merit Loan bore interest at 5% per annum, compounded annually, payable by way of a lump sum balloon payment at the end of the term. Concurrent with the termination of the LC on August 28, 2020, the Merit Loan Agreement was also terminated on the same date. For the year ended March 31, 2021, Burcon recorded interest income of $120,205 (2020 - $ nil nil nil In addition, Burcon provided a guarantee to EDC and FCC in connection with the $85 million financing package (the "Guarantees"), pursuant to which Burcon agreed to guarantee all of the indebtedness, liabilities and obligations to Merit Foods under the loan agreements between EDC, FCC and Merit Foods. The aggregate maximum liability of Burcon under the Guarantees was limited to $4.0 million. As part of the investment by Bunge into Merit Foods, EDC and FCC released the Guarantees on August 28, 2020. In June 2020, Burcon announced that Merit Foods had secured additional debt financing of $10 million in the form of a 10-year interest-free loan from Agriculture and Agri-Food Canada (the "AIP Loan"). Burcon Holdings and the Partners provided a guarantee for the AIP Loan (the "AIP Guarantee"). The obligations of the AIP Guarantee are joint and several. However, Burcon Holdings and the Partners (the "AIP Guarantors") have entered into a reciprocal indemnity agreement (the "Indemnity Agreement'). Under the Indemnity Agreement, if any AIP Guarantor (each, a "Paying Guarantor") is required to make payment under the AIP Guarantee and any other AIP Guarantor (each, a "Contributing Guarantor") has not made a corresponding payment equal to its share based on its shareholdings in Merit Foods ("Contributive Share"), such Contributing Guarantor(s) shall pay the Paying Guarantor such amounts so that, after payment, all obligations and liabilities under the AIP Guarantee will have been borne by the AIP Guarantors in their respective shareholding percentage in Merit Foods. In total, Merit Foods secured a total of $99.2 million financing package from the Government of Canada that includes the financing noted above from EDC, FCC, AIP and Protein Industries Canada ("PIC"). In addition to the co-investment received by Merit Foods from PIC, a further co-investment by PIC to Merit Foods was announced in May 2021 to develop new plant-based products. The project has a total investment of $7.9 million, with PIC funding one-half of the total investment into the project.

Deferred revenue

Deferred revenue	12 Months Ended
	Mar. 31, 2021
Disclosure Of Deferred Revenue [Abstract]
Deferred revenue [Text Block]	6. Deferred revenue In January 2020, Burcon, Société Des Produits Nestlé ("Nestlé ") and Merit Foods entered into a joint development agreement (the "JDA") to tailor Burcon and Merit's plant-based proteins for use in Nestlé food and beverage applications. The JDA covered ongoing innovation and the future supply of Burcon and Merit’s plant-based proteins from the Flex Production Facility. The partnership was intended to combine Nestlé’s expertise in the development, production and commercialization of plant-based foods and beverages with Burcon’s proprietary plant protein extraction and purification technology, while leveraging Merit Foods’ plant protein production capabilities. During the year, Burcon conducted research work and provided various samples to Nestlé for testing and analysis. The research conducted by Burcon was successful in identifying processing techniques to modify and improve the functionality of Burcon’s and Merit’s plant-based proteins and as such, Burcon’s role in the JDA ended in January 2021, Merit has continued to work with Nestlé for the supply of Merit Foods’ plant protein products. During the year, Burcon recorded $250,000 that was received in fiscal 2020 from Nestlé as research income.

Convertible debentures and conv

Convertible debentures and convertible note	12 Months Ended
	Mar. 31, 2021
Borrowings [abstract]
Convertible debentures and convertible note [Text Block]	7. Convertible debentures and convertible note Convertible debentures On December 10, 2019, the Company issued convertible debentures (the "Debentures") through a non-brokered private placement for an aggregate principal amount of $9.5 million. Certain directors and an officer of the Company subscribed for Debentures totalling $2 million in principal amount. Each Debenture consisted of $1,000 principal amount, bore interest at a rate of 8.5% per annum, payable semi-annually in arrears and was unsecured. The principal amount outstanding under the Debentures and all accrued and unpaid interest thereon were to be payable in cash on December 10, 2022. The Company incurred issue costs of $228,432, of which $156,600 were finder's fees at 4.5% of the gross proceeds received from investors introduced to the Company by the finders. The Debentures were convertible at the option of the holder, in whole or in part, into common shares of the Company at a conversion price of $1.05 per share. During the year, the holders of the Debentures converted principal amounts of $1,704,500 for the issuance of 1,623,327 common shares of the Company. Burcon had the right, at its sole discretion, to force the conversion of the Debentures if the shares traded at or above $2.15 for a period of 14 consecutive trading days. The Company determined it had met this condition between August 12 to August 31, 2020 and issued a notice to the holders of the Debentures for conversion of the Debentures to common shares on September 8, 2020. As a result of the conversion of $7,795,500 of outstanding principal amount of the Debentures, an aggregate of 7,424,274 common shares were issued to the holders of the Debentures. The Debentures were a level 3 financial liability with an embedded conversion feature. The debt and equity components were bifurcated, and the instrument valued to par at the issuance date. The value assigned to the liability at December 10, 2019 was the present value of the contractually determined stream of future cash flows discounted at 24%, being the rate estimated to be equivalent to that which the market would apply to an instrument with comparable credit status and provide substantially the same cash flows, on the same terms, but without the conversion option. From the date of issuance, the liability component was accreted up to its principal value using the effective interest method, with the charge recorded in the consolidated statement of operations and comprehensive income (loss). The initial fair value of the debt as at December 10, 2019 was estimated to be $6,508,641. The residual amount of $2,762,927 was recognized within equity as the value of the conversion option. For the year ended March 31, 2021, the Company recorded interest expense of $637,522 (2020 - $ nil Convertible note The Company had a convertible note (the "Note") with Large Scale Investments Limited ("Large Scale'), a wholly owned subsidiary of Firewood Elite Limited ("Firewood"), for the principal amount of $2.0 million (the "Principal Amount"). The Note bore interest at 8% per annum, compounded monthly. Firewood, a related party of Burcon that has significant influence over the Company, is wholly owned by Mr. Alan Chan, a director of the Company. On May 21, 2019, the Company and Large Scale amended (the "Amendment") the Note's Maturity Date to June 21, 2019, as well as providing Large Scale with the right to offset any amounts due to it under the Note against any obligations of Large Scale to pay for subscription proceeds of any rights offering that Burcon may conduct. In connection with the 2019 Rights Offering (note 9(a)), Large Scale exercised its right to offset the amounts due under the Note against its obligations to pay for subscription proceeds under the 2019 Rights Offering. The offset was completed on June 25, 2019. The total amount offset under the Note included the principal amount and accrued interest of $2,565,022. The conversion option was recorded as a derivative liability (note 16). Under the terms of the Note, there are certain conditions where the conversion price may be adjusted. Therefore, in accordance with IFRS, an obligation to issue shares for a price that is not fixed must be classified as a derivative liability and measured at fair value, with changes recognized in change in fair value of conversion option in the consolidated statement of operations and comprehensive loss. The conversion and prepayment options were recorded as a net derivative liability and measured at fair value, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss. The fair value of the conversion and prepayment options was estimated based on a methodology for pricing convertible bonds using the Partial Differential Equation Method, with the following initial assumptions: expected volatility of 63%; expected dividend per share of $nil; risk-free rate of 0.60%, entity-specific credit spread, and expected life of 3 years. The assumptions as at March 31, 2019 were as follows: expected volatility of 99%, expected dividend per share of $nil; risk-free rate of 1.63%, initial entity-specific credit spread adjusted by the movement in the option adjusted spread of the Canada High Yield Index, and expected life of 1.1 years. The initial fair value of the net derivative liability was estimated as $189,705 as at the issue date of the Note. As at March 31, 2019, the fair value of the net derivative liability was estimated to be $5,384. Upon the offset by Large Scale of its obligations to pay for subscription proceeds under the 2019 Rights Offering, the net derivative liability was expensed during fiscal 2020 as financing expense.

Short-term loan

Short-term loan	12 Months Ended
	Mar. 31, 2021
Disclosure of detailed information about borrowings [abstract]
Short-term loan [Text Block]	8. Short-term loan The Company had a short-term loan with Large Scale to provide Burcon with an unsecured loan for up to $1.5 million (the "Loan").The Loan bore interest at 18% per annum on the amount drawn, and 3% per annum on the undrawn portion. The Loan provided the Lender with the right to offset any amount due to it under the Note against any obligations of the Lender to pay for subscription proceeds of any rights offering that Burcon may conduct. In connection with the 2019 Rights Offering (note 9(a)), Large Scale exercised its right to offset the amounts due under the Loan against its obligations to pay for subscription proceeds under the 2019 Rights Offering. The offset was completed on June 25, 2019 for $1,436,629 against the principal amount. The balance of the principal amount of $63,371 and accrued interest of $107,173 was repaid to Large Scale in cash on June 28, 2019.

Shareholders' equity

Shareholders' equity	12 Months Ended
	Mar. 31, 2021
Equity [abstract]
Shareholders’ equity [Text Block]	9. Shareholders’ equity a) Authorized Unlimited number of common shares without par value 2020 Equity Offering On February 19, 2020, the Company completed a bought deal equity offering of 7,419,800 units (the "Units") at a price of $1.55 per Unit for aggregate gross proceeds to the Company of $11.5 million (the "Offering") and net proceeds of $10.3 million. Each Unit consisted of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share (a "Warrant Share") until February 19, 2022 at an exercise price of $2.00 per Warrant Share. The fair value of the Warrants was estimated at $1,780,752 using the Black-Scholes pricing model. During the year ended March 31, 2021, warrants were exercised for 2,285,500 Warrant Shares, providing proceeds of $4,571,000 to the Company. As March 31, 2021, 1,424,400 Warrants were outstanding. The agents received a cash commission of 7% of the gross proceeds and compensation options (Agents' Warrants) entitling the agents to purchase up to 519,386 common shares. Each Agent's Warrant is exercisable to acquire one common share of the Company at an exercise price of $2.00 per share until February 19, 2022. The fair value of the Agents' Warrants was estimated at $249,305 using the Black-Scholes pricing model. During the year ended March 31, 2021, 207,754 Agents' Warrants were exercised, providing proceeds of $415,508 to the Company. At March 31, 2021, 311,632 Agents' Warrants were outstanding. In addition to the Agents' Warrants, the Company incurred total issue costs of $1.2 million related to the Offering. 2019 Rights Offering On June 25, 2019, the Company completed a rights offering (the "2019 Rights Offering") for 44,083,203 common shares at $0.35 per common share for gross proceeds of $15,429,121, and net proceeds of $15,284,430. Burcon issued to each shareholder as of the record date of May 30, 2019 one transferrable right (the "2019 Rights") for each common share held by such shareholder. Every 2019 Right entitled the holder thereof to purchase one common share in the Company at a price of $0.35 per common share. The Company's directors, officers and persons controlling over 10% of the common shares of the Company agreed to exercise at least all of the 2019 Rights they were issued in connection with the 2019 Rights Offering for 14,306,740 common shares, representing 32.5% of the 2019 Rights Offering. Of the net proceeds of the 2019 Rights Offering, $2,565,022 were used to repay the Note and accrued interest to Large Scale (note 7) and $1,607,183 has been used to repay the Loan and accrued interest to Large Scale (note 8). b) Contributed surplus comprises the value ascribed to expired warrants and options and forfeited vested options, previously categorized in either warrants or options, as applicable, within shareholders’ equity. c) Options The Company has a stock option plan in which all directors, officers, employees and consultants of the Company and its subsidiary are eligible to participate. At March 31, 2021, 4,949,106 (2020 - 4,507,606) options to purchase common stock are outstanding from the stock option plan. These options, when vested under the terms of the plan, are exercisable at prices ranging between $0.23 and $8.05 per common share. An additional 5,894,031 (2020 - 5,172,357) options may be granted in future years under this plan. Unless otherwise determined by the board of directors, the options have a term of up to 10 years from the date of grant. The vesting terms are determined at the discretion of the board of directors at the time of grant. All grants are recognized using graded vesting, with each vesting tranche being valued separately, and the fair value of each tranche recognized over its respective vesting period. 2021 2020 Number of Weighted $ Number of Weighted $ Outstanding - Beginning of year 4,507,606 3.32 3,953,739 3.46 Granted 1,253,000 3.95 757,000 1.88 Exercised (94,000 ) 0.56 (173,000 ) 0.41 Expired (717,500 ) 9.51 — — Cancelled — — (30,133 ) 1.96 Outstanding - End of year 4,949,106 2.63 4,507,606 3.32 The following table summarizes information about stock options outstanding and exercisable at March 31, 2021: Options outstanding Options exercisable Range of Number outstanding at March 31, 2021 Weighted average remaining contractual (years) Weighted average exercise price $ Number exercisable at March 31, 2021 Weighted average exercise price $ 0.23 - 0.69 832,333 7.50 0.39 672,666 0.43 1.88 - 4.73 4,016,773 5.80 2.98 2,930,770 2.83 6.78 - 8.05 100,000 0.57 7.54 100,000 7.54 4,949,106 5.98 2.63 3,703,436 2.52 The fair value of each option is estimated as at the date of grant or other measurement date using the Black-Scholes option pricing model and the following weighted average assumptions: 2021 2020 Dividend yield 0.0% 0.0% Expected volatility 78.5 75.1 Risk-free interest rate 0.5 1.3% Expected forfeitures 7.2% 7.7 Expected average option term (years) 6.7 7.9 The expected forfeitures are based on historical forfeitures. The expected volatility is based on historical volatility and also historical volatilities of a group of comparable public companies. The risk-free rate of return is the yield on a zero-coupon Canadian treasury bill of a term consistent with the expected average option term. The expected average option term is the average expected period to exercise, based on the historical activity patterns for each individually vesting tranche. The weighted average fair value of the options granted during the year ended March 31, 2021 was $2.73 (2020 - $1.36) per option. Included in research and development expenses is $7,706 (2020 - $16,757) (note 10) and in general and administrative expenses (salaries and benefits) is $1,550,828 (2020 - $469,472) (note 11) of stock-based compensation. Included in deferred development costs is $319,610 (March 31, 2020 - $50,660) (note 4) of stock-based compensation.

Research and development

Research and development	12 Months Ended
	Mar. 31, 2021
Disclosure Of Research And Development Expense [Abstract]
Research and development [Text Block]	10. Research and development 2021 $ 2020 $ Salaries and benefits (note 9) 1,602,709 1,317,920 Laboratory operation 305,135 290,336 Amortization of property and equipment 225,180 72,187 Rent 108,346 87,720 Analyses and testing 62,874 55,740 Travel and meals — 16,554 Gross research and development expenses 2,304,244 1,840,457 Allocated to deferred development costs (1,163,856 ) (655,132 ) Allocated to inventory production (726,383 ) (463,474 ) Net research and development expenses 414,005 721,851 Research and development expenses have been reduced by COVID-19 subsidies of $115,013 (2021 - $nil) from the Canada Emergency Wage Subsidy ("CEWS") and Canada Emergency Rent Subsidy programs ("CERS"), as well as a Manitoba government training grant of $45,099 (2020 - $21,529).

General and administrative

General and administrative	12 Months Ended
	Mar. 31, 2021
Selling, general and administrative expense [abstract]
General and administrative [Text Block]	11. General and administrative 2021 $ 2020 $ Salaries and benefits (note 9) 2,635,873 1,350,824 Professional fees 465,226 274,356 Investor relations 247,735 131,646 Office supplies and services (note 13) 170,494 165,050 Transfer agent and filing fees 57,030 27,289 Amortization 47,474 1,949 Financing expense (notes 5 and 13) 23,790 88,920 Other 6,272 3,788 Travel and meals 248 66,225 Rent — 76,226 3,654,142 2,186,273 Salaries and benefits have been reduced by $145,765 from COVID-19 subsidies received from the CEWS program.

Basic and diluted loss per shar

Basic and diluted loss per share	12 Months Ended
	Mar. 31, 2021
Basic and diluted earnings per share [abstract]
Basic and diluted loss per share [Text Block]	12. Basic and diluted loss per share The following table sets forth the computation of basic and diluted loss per share: 2021 $ 2020 $ Loss for the year, being loss attributable to common shareholders - basic and diluted (617,492 ) (4,633,494 ) Weighted average common shares - basic and diluted 102,890,726 78,935,751 Basic and diluted loss per share (0.01 ) (0.06 ) For the years ended March 31, 2021 and 2020, the Company excluded all potential common share equivalents from the diluted loss per share calculation as they were anti-dilutive.

Related party transactions

Related party transactions	12 Months Ended
	Mar. 31, 2021
Related party transactions [abstract]
Related party transactions [Text Block]	13. Related party transactions The Company engaged an entity that is related by virtue of common officers for the following related party transactions: For the year ended March 31, 2021, the Company made payments of $4,584 (2020 - $75,006) for office space rental. For the year ended March 31, 2021, included in general and administrative expenses (management fees) are $2,241 (2020 - $1,181), for services provided to the Company. At March 31, 2021, $75 (2020 - $11) of this amount is included in accounts payable and accrued liabilities. For the year ended March 31, 2021, included in interest and other income is $7,709 (2020 - $14,197) for management services provided by the Company. At March 31, 2021, $437 (2020 - $1,785), of this amount is included in amounts receivable. Burcon has a Services Agreement with Merit Foods to provide technical, administrative and general management services, research and analytical services and sample production services based on rates set out in the Services Agreement. (See note 5 for details). In connection with the LC, Burcon Holdings entered into the Merit Loan Agreement with Merit Foods in the amount of $6.5 million. During the year ended March 31, 2021, Burcon recorded interest income of $120,205 (2020 - $ nil nil nil Certain directors and an officer subscribed for $2.0 million of the Debentures. During the year ended March 31, 2021, the Company made total convertible debenture interest payments of $126,803 to these directors and officer. Burcon had the Loan (note 8) and Note (note 7) with Large Scale, a company that is wholly owned by Firewood. For the year ended March 31, 2020, included in interest expense is $56,502 related to the Note and $60,756 related to the Loan. Upon completion of the 2019 Rights Offering, the exercise price for the share purchase warrants issued to Dr. Yap, former chief executive officer of the Company, was adjusted from $0.69 per share to $0.45 per share. The Company recorded $85,420 as financing expense during fiscal 2020. During the year ended March 31, 2020, Dr. Yap exercised the warrants for 1,182,099 common shares.

Key management compensation

Key management compensation	12 Months Ended
	Mar. 31, 2021
Disclosure Of Key Management Compensation [Abstract]
Key management compensation [Text Block]	14. Key management compensation Key management includes the Company's Chief Executive Officer. Remuneration of directors and key management personnel comprises: 2021 $ 2020 $ Short-term benefits 491,012 387,822 Option-based awards 1,367,502 372,223 1,858,514 760,045 Short-term benefits comprise salaries, director fees and employment benefits. Option-based awards represent the cost to the group of senior management and directors' participation in the incentive stock option plan, as measured by the fair value of instruments granted accounted for in accordance with IFRS 2, Share-based Payment. For details of these plans refer to note 9 to the consolidated financial statements.

Income taxes

Income taxes	12 Months Ended
	Mar. 31, 2021
Major components of tax expense (income) [abstract]
Income taxes [Text Block]	15. Income taxes The recovery of income taxes differs from the amount obtained by applying the statutory Canadian federal and provincial income tax rates to loss for the year as follows: 2021 $ 2020 $ Recovery of income taxes based on the combined statutory income tax rate of 27.0% (2020 - 27.0%) (167,000 ) (1,251,000 ) Changes in unrecognized deferred tax assets (414,000 ) 1,384,000 Financing costs (1,000 ) (316,000 ) Non-deductible items and tax adjustments 582,000 183,000 Recovery of income taxes — — As at March 31, 2021 the Company has non-capital losses of approximately $62,755,000 (2020 - $58,032,000) available to reduce taxable income in future years. These losses expire as follows: $ 2026 800,000 2027 1,124,000 2028 1,344,000 2029 1,596,000 2030 2,691,000 2031 4,358,000 2032 5,327,000 2033 4,606,000 2034 5,507,000 2035 5,623,000 2036 4,895,000 2037 4,612,000 2038 5,303,000 2039 5,215,000 2040 4,472,000 2041 5,282,000 62,755,000 In addition, the Company has SR&ED expenditures of approximately $15,130,000 available to carry forward indefinitely. ITCs of $5,032,000 may be used to offset deferred income taxes otherwise payable and expiring between 2022 and 2040. For the year ended March 31, 2021, included in interest and other income is $ nil 2021 $ 2020 $ Deferred income tax assets (liability) SR&ED expenditures 4,073,000 4,073,000 Losses from operations carried forward 16,943,000 15,668,000 Investment in Merit Foods (918,000 ) 215,000 Deferred development costs (962,000 ) (386,000 ) Interest expense — (2,000 ) Financing costs 245,000 334,000 Property and equipment 245,000 132,000 Right-of-Use assets/liability (5,000 ) — Unrecognized deferred income tax assets 19,621,000 20,034,000 Management believes the realization of income tax benefits related to these losses and other potential deferred income tax assets is uncertain at this time and cannot be viewed as probable. Accordingly, the Company has not recognized these deferred income tax assets.

Financial instruments

Financial instruments	12 Months Ended
	Mar. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Financial instruments [Text Block]	16. Financial instruments Credit risk The financial instruments that expose the Company to a concentration of credit risk are cash and cash equivalents and amounts receivable. The Company's cash and cash equivalents may comprise interest-bearing savings instruments with Canadian chartered banks. The Company limits its exposure to credit loss by placing its cash and cash equivalents with two Canadian chartered banks. An expected credit loss provision of $74,193 has been recognized in relation to the loan to Merit Foods and included in interest and other expense on the consolidated statement of operations and comprehensive loss. Interest rate risk All of the Company's financial instruments are non-interest bearing except for cash and cash equivalents that earn interest at variable market rates, and the loan to Merit Foods that bore interest at a fixed interest rate. Burcon's cash and cash equivalents are held at two Canadian chartered banks to maximize interest and to diversify risk. For the year ended March 31, 2021, the weighted average interest rate earned on the Company's cash and cash equivalents was 0.36% per annum (2020 - 1.92% per annum). The impact of a 1% strengthening or weakening of interest rates on the Company's cash and cash equivalents at March 31, 2021 is estimated to be a $140,000 increase or decrease in interest income per year. Liquidity risk The Company manages liquidity risk through the management of its capital structure (note 16). It also manages liquidity risk by monitoring actual and forecasted cash flows taking into account current and planned operations. The Company's estimated minimum contractual undiscounted cash flow requirement for its financial liabilities at March 31, 2021 is $1,418,049, all of which is due within the next 12 months. Fair value The fair value of the Company's short-term financial assets and financial liabilities, including cash and cash equivalents, amounts receivable, accounts payable and accrued liabilities and accrued interest, approximates their carrying values due to the short-term maturities of these financial instruments. The carrying values and fair values of financial instruments, by class, are as follows as at March 31, 2021 and 2020: As at March 31, 2021 At fair value Financial Financial Fair value Financial assets $ $ $ $ Cash and cash equivalents — 13,972,659 — 13,972,659 Amounts receivable — 338,715 — 338,715 Loan to Merit Foods — 2,893,511 — 2,967,704 Total — 17,204,885 — 17,279,078 Financial liabilities Accounts payable and accrued liabilities — — 1,418,049 1,418,049 Total — — 1,418,049 1,418,049 As at March 31, 2020 At fair value Financial Financial Fair value Financial assets $ $ $ $ Cash and cash equivalents — 15,030,988 — 15,030,988 Amounts receivable — 332,248 — 332,248 Loan to Merit Foods — 2,659,830 — 2,659,830 Total — 18,023,066 — 18,023,066 Financial liabilities Accounts payable and accrued liabilities — — 1,067,251 1,067,251 Accrued interest — — 249,310 249,310 Convertible debentures — — 6,731,350 6,731,350 Total — — 8,047,911 8,047,911 Currency risk The Company has not hedged its exposure to currency fluctuations. As at March 31, 2021 and 2020, the Company is exposed to currency risk through the following assets and liabilities denominated in U.S. dollars: March 31, March 31, U.S. Dollars Cash and cash equivalents $ 27,752 $ 21,819 Amounts receivable 1,851 2,528 Accounts payable and accrued liabilities — (40,556 ) Net exposure $ 29,603 $ (16,209 ) Canadian dollar equivalent $ 37,226 $ (22,996 ) Based on the above net exposure at March 31, 2021, a 10% appreciation or depreciation of the U.S. dollar against the Canadian dollar would have resulted in an increase/decrease of approximately $3,000 (March 31, 2020 - $2,000) in the Company's loss from operations. Capital disclosures The Company considers its capital to be its shareholders' equity. The Company manages its capital structure to have sufficient resources available to meet day-to-day operating requirements, continue as a going concern and fund its research and development program. The Company is dependent on non-operating sources of cash, primarily from issuing equity and debt, to fund its operations and research development programs. The Company monitors its capital and the expected cash flows required to achieve its business objectives to determine its future financing needs. It seeks additional capital when deemed appropriate, but there is no assurance that it will be able to secure the necessary capital when required. The Company is not subject to externally imposed capital requirements and there has been no change with respect to the overall capital risk management strategy during the year ended March 31, 2021.

Subsequent events

Subsequent events	12 Months Ended
	Mar. 31, 2021
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent events [Text Block]	17. Subsequent events Subsequent to the year-end: a) Warrants were exercised for 45,750 Warrant Shares for proceeds of $91,500; b) 12,300 options were exercised at a weighted average exercise price of $0.85. c) 88,000 options were granted to employees at an exercise price of $4.89 per share.

COVID-19

COVID-19	12 Months Ended
	Mar. 31, 2021
Covid 19 [Abstract]
COVID-19 [Text Block]	18. COVID-19 The COVID-19 outbreak was declared as a pandemic by the World Health Organization on March 11, 2020. Globally, governments worldwide have focused on containment of the outbreak and the prevention of further spread. Since the outbreak, global economies have been impacted as governments have imposed restrictions such as travel bans, self-imposed quarantines, social distancing and temporary closures of non-essential businesses. While economies began to slowly reopen in June 2020 after an initial lockdown, governments were required to reinstate lockdowns and closures when infection rates returned at the end of 2020 and early 2021. Since March 2021, the supply of vaccines has become more secure in Canada and immunization rates are continuing to improve in Canada, the United States and may developed countries in the world. The duration and long-term effects of the pandemic is unknown at this time. In response to the COVID-19 pandemic, Burcon implemented measures to ensure the safety of work conditions for its staff at the Winnipeg Technical Centre and at its head office in Vancouver. While the COVID-19 pandemic has not had significant adverse effect on Burcon's and Merit Foods' business operations to-date, it is not possible to predict how long the pandemic will continue to last and whether the financial and business conditions of Burcon and Merit Foods will be impacted in future periods. Governments worldwide, including Canada, have implemented significant monetary and fiscal relief programs designed to stabilize their economies. Burcon has received Canadian government assistance through the CEWS and CERS programs. See notes 10 and 11 for details.

Significant accounting polici_2

Significant accounting policies (Policies)	12 Months Ended
	Mar. 31, 2021
Disclosure Of Significant Accounting Policies [Abstract]
Basis of presentation [Policy Text Block]	Basis of presentation These consolidated financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and interpretations issued by the IFRS Interpretations Committee (“IFRIC”). The Company has consistently applied the same accounting policies throughout all periods presented. Certain comparatives have been restated to conform with this year's presentation. The board of directors approved these consolidated financial statements on June 24, 2021.
Principles of consolidation [Policy Text Block]	Principles of consolidation These consolidated financial statements include the accounts of the Company and its subsidiaries, Burcon NutraScience (MB) Corp. ("Burcon-MB") and Burcon NutraScience Holdings Corp. ("Burcon Holdings"). A subsidiary is an entity in which the Company has control, directly or indirectly. Under IFRS 10, an investor controls an investee if and only if the investor has power over the investee, exposure, or rights, to variable returns from its involvement with the investee, and the ability to use its power over the investee to affect the amount of the investor's returns. All material intercompany transactions and balances have been eliminated on consolidation. Details of the Company's subsidiaries at March 31, 2021 are as follows: Place of incorporation Interest % Principal activity Burcon NutraScience (MB) Corp. Manitoba, Canada 100 Research and development Burcon NutraScience Holdings Corp. Canadian federally incorporated 100 Investment holding
Investment in Associates [Policy Text Block]	Investment in Associates An associate is an entity over which the Company has significant influence. Significant influence is the power to participate in the financial and operating policy of the investee without the power to control or jointly control those policies. The results and assets and liabilities of associates are incorporated in these consolidated financial statements using the equity method of accounting. Under the equity method of accounting, investments are recorded at historical cost as an asset and adjusted for dividends received, capital contributions, other transactions that result in changes in ownership interest held by the Company, and the Company's share of Merit's earnings or losses, which is recorded as a component of Loss and Comprehensive Loss for the year. When the Company's share of losses of an associate exceeds the Company's interest in the associate, which includes any long-term interests that, in substance, form part of the Company's net investment in the associate, the Company discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate. Management considers whether there are any indicators of impairment to determine whether it is necessary to recognize any impairment loss with respect to the Company's investment in an associate. When such indicators of impairment exist, the carrying amount of the investment is tested for impairment by comparing the recoverable amount with its carrying amount of the investment. Any reversal of that impairment loss is recognized to the extent that the recoverable amount of the investment subsequently increases.
Revenue recognition [Policy Text Block]	Revenue recognition The Company recognizes revenue when the amount of revenue can be reliably measured, and it is probable that future economic benefits will flow to the Company. The Company may earn revenues from licensing agreements under which third parties are granted rights to use the Company's technologies. If the substantive rights to the technologies are retained by the Company, or the Company has remaining performance obligations under the licensing agreements, and as such not all of the risks and rewards have been transferred to the licensee, the Company recognizes amounts received or receivable as royalties when earned on an accrual basis. At the point when all of the risks and rewards associated with the use of the technologies have, in substance, been relinquished under the licensing agreements, the Company recognizes the fair value of future payments expected to be received as proceeds from the sale of the technologies in the consolidated statements of operations and comprehensive loss, once the expected future payments can be reliably measured. Upfront payments and similar non-refundable payments received under these agreements are initially recognized as deferred revenue. Subsequently, if the Company recognizes royalty revenue, the amounts deferred are recognized as revenue on a straight-line basis over the estimated period royalties are expected to be earned commencing in the period royalties are first recognized as revenue. Otherwise, the deferred amounts are recognized as sale proceeds at the date of sale of the technologies. License agreements may consist of multiple elements and provide for varying consideration terms, such as upfront payments and milestone or similar payments. Revenue arrangements with multiple elements are reviewed in order to determine whether the multiple elements can be divided into separate units of accounting. If separable, the consideration received is allocated among the separate units of accounting based on their respective fair values, and the applicable revenue recognition criteria are applied to each of the separate units. Otherwise, the applicable revenue recognition criteria are applied to the revenue arrangement as a single unit.
Government assistance [Policy Text Block]	Government assistance The Company carries out research and development in Canada that is eligible for Scientific Research and Experimental Development ("SR&ED") Investment Tax Credits ("ITC") at both the federal and provincial level. The Company has recognized the refundable portion of ITC at the provincial level but has not recognized the benefits of ITC at the federal level because realization of these benefits is not probable at this time. The Company's determination of ITC involves uncertainty with respect to management's interpretation of complex tax regulations. The ITC claims are subject to review and acceptance by the Canada Revenue Agency prior to collection. Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Company with no future related costs are recognized in the statement of profit or loss in the period in which they become receivable.
Accounting estimates and judgments [Policy Text Block]	Accounting estimates and judgments The preparation of consolidated financial statements in accordance with IFRS requires management to apply judgment when making estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements, the reported amount of revenue and expenses during the reporting period, and disclosures made in the accompanying notes to the consolidated financial statements. Actual results may differ from those estimates. The significant areas where management's judgment is applied are in determining the fair value of stock-based compensation (see note 9 for assumptions used by management), whether all criteria for deferring development costs are met, the point at which amortization of development costs commences, the expense allocation to deferred development costs and the recoverable amounts of investment in associates, expected credit losses on loans receivable, goodwill, and the discount rate used to fair value the loans receivable from Merit Foods following their modification (note 5).
Cash and cash equivalents [Policy Text Block]	Cash and cash equivalents Cash and cash equivalents consist of cash on deposit with banks and highly liquid short-term interest bearing securities with maturities at the date of purchase of three months or less.
Financial instruments [Policy Text Block]	Financial instruments Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. Financial assets and liabilities are offset and the net amount is reported in the consolidated balance sheets when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the asset and settle the liability simultaneously. At initial recognition, the Company classifies its financial instruments in one of the following categories: amortized cost, fair value through profit or loss, and fair value through other comprehensive income. Derivatives are recognized initially and subsequently at fair value. Transaction costs are expensed in the consolidated statements of operations and comprehensive loss. Gains and losses arising from changes in fair value are presented in the consolidated statements of operations and comprehensive loss, through profit or loss, in the period in which they arise. Financial assets carried at amortized cost, which include loans and receivables initially recognized at the amount expected to be received, less a provision for the expected credit loss. Subsequently, financial assets carried at amortized cost are measured at amortized cost using the effective interest method less a provision for the expected credit loss. The Company classifies its cash and cash equivalents and amounts receivable as financial assets carried at amortized cost. Other financial liabilities are initially recognized at the amount required to be paid, less, when material, a discount to reduce the payables to fair value. Subsequently, other financial liabilities are measured at amortized cost using the effective interest method. At each reporting date, the Company assesses whether there is objective evidence that a financial asset is impaired. If such evidence exists, the Company recognizes an impairment loss, as follows: Financial assets carried at amortized cost: the impairment loss is the difference between the carrying value of the asset and the amortized cost of the financial asset, less the expected credit loss. The carrying amount of the asset is reduced by this amount which is recognized in the consolidated statements of operations and comprehensive loss, through profit or loss. Impairment losses on financial assets carried at amortized cost are reversed in subsequent periods if the amount of the expected credit loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized. Transaction costs of an equity transaction are accounted for as a deduction from equity to the extent that they are incremental costs directly attributable to the equity transaction that otherwise would have been avoided. Qualifying transaction costs incurred prior to the Company's year-end in anticipation of an issuance of equity instruments subsequent to the Company's year-end are deferred on the consolidated balance sheets until the equity instruments are issued.
Property and equipment [Policy Text Block]	Property and equipment Property and equipment are recorded at cost less accumulated amortization. The Company provides for amortization at the following annual rates: Equipment 20% declining balance Computer equipment 30% declining balance Leasehold improvements Straight-line over lease term Right-of-use assets Straight-line over lease term
Inventories [Policy Text Block]	Inventories Inventories are recorded at the lower of cost and net realizable value.
Impairment of long-lived assets [Policy Text Block]	Impairment of long-lived assets The Company tests property and equipment for impairment whenever events or circumstances indicate that the carrying value of an asset or group of assets may not be recoverable. Intangible assets that are not being amortized are tested annually for impairment and also if the Company identifies indicators of impairment. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash inflows (cash-generating units). The evaluation is based on the higher of the asset's fair value less costs of disposal and its value in use, which is the present value of future cash flows expected to be derived from the asset in its current state. An impairment loss is recognized in the period it is determined to the extent that the carrying value exceeds the higher of fair value less costs to sell and value in use of the asset or group of assets.
Research and development costs [Policy Text Block]	Research and development costs Research costs are expensed in the year incurred. Development costs are also expensed in the year incurred unless the related process is clearly defined and the costs attributable thereto can be reliably measured; the technical feasibility of the process has been established so that it will be available for use or sale; management has indicated its intention to produce and market, or use, the process; an ability to use or sell the process exists; the process will generate probable future economic benefits; and adequate resources exist, or are expected to be available, to complete the development and to use or sell the process. On July 1, 2019, the Company commenced deferring development costs related to its pea and canola technologies. The deferred development costs will be amortized on a straight-line basis over their estimated useful lives commencing on the date the Company starts earning royalties.
Goodwill [Policy Text Block]	Goodwill Goodwill represents the excess at the date of acquisition of the cost of the acquired business over the fair values attributed to the underlying net tangible assets and the identifiable intangible assets. Goodwill is not amortized. On at least an annual basis, or when circumstances indicate the carrying value of goodwill may not be recoverable, the Company subjects goodwill to an impairment test. For impairment testing purposes, the carrying value of goodwill is allocated to the group of assets that realize the benefits of the acquisition. The impairment assessment is performed by comparing the carrying value of the group of assets, including the allocated carrying value of goodwill, to the higher of its fair value less costs to sell and its value in use, which is the present value of future cash flows expected to be derived from the group of assets in their current state. If the carrying amount of the group of assets exceeds the recoverable amount, an impairment loss is charged to operations in the period such impairment is identified, allocated first to reducing the carrying amount of the goodwill allocated to the group, and then to the other assets of the group.
Income taxes [Policy Text Block]	Income taxes The Company uses the balance sheet liability method of accounting for income taxes. Under this method, current income taxes are recognized for the estimated income taxes payable for the current year. Deferred income tax assets and liabilities are recognized in the current year for temporary differences between the tax and accounting bases of assets and liabilities as well as for the benefit of losses available to be carried forward to future years for tax purposes. Deferred income tax assets and liabilities are measured using substantively enacted tax rates and laws expected to apply in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax assets are recognized only to the extent they are considered probable to be realized.
Stock-based compensation [Policy Text Block]	Stock-based compensation The Company accounts for stock-based compensation granted to employees using the fair value method calculated using the Black-Scholes option pricing model. Stock-based compensation granted to non-employees is measured at the fair value of the goods and services received unless the fair value cannot be measured reliably, in which case the amount is measured using the fair value of the options granted. For options granted to employees and those providing similar services, including officers and directors, the compensation cost is measured at the fair value of the equity instrument granted at the date of grant and is expensed to operations over the award's vesting period. When stock options are exercised, capital stock is credited by the sum of the consideration paid and by the related portion previously recorded in options. Additional information related to the stock option plan and the assumptions used in the Black-Scholes option pricing model are provided in note 9(c).
Loss per share [Policy Text Block]	Loss per share Basic loss per share is computed by dividing the net loss for the year available to common shareholders by the weighted average number of common shares outstanding during the year. The Company applies the treasury stock method to calculate diluted loss per share. Diluted loss per share excludes all dilutive potential common shares if their effect is anti-dilutive.
Foreign currency translation [Policy Text Block]	Foreign currency translation a) Items included in the financial statements of each consolidated entity are measured using the currency of the primary economic environment in which the entity operates (the "functional currency"). These consolidated financial statements are presented in Canadian dollars, which is the Company's and its subsidiaries' functional currency. b) Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the date of the transactions. Generally, foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in currencies other than an operation's functional currency are recognized in the consolidated statements of operations and comprehensive loss.
Newly adopted accounting standards and amendments [Policy Text Block]	Newly adopted accounting standards and amendments IFRS 16 - Leases Effective April 1, 2019, the Company adopted IFRS 16 - Leases, which requires, among other things, leases to recognize leases traditionally recorded as operating leases in the same manner as a financing lease. The Company applied IFRS 16 on a modified retrospective basis and it did not have a significant impact on the consolidated financial statements.
Accounting standard and amendments issued and not yet adopted [Policy Text Block]	Accounting standard and amendments issued and not yet adopted Amendments to IAS 1 - Classification of Liabilities as Current or Non-Current The amendment clarifies the classification requirements to determine if a liability should be presented as current or non-current in the statement of financial position. Under the new requirement, the assessment of whether a liability is presented as current or non-current is based on the contractual arrangements in place as at the reporting date and does not impact the amount or timing or recognition. The amendment is effective for annual reporting periods beginning on or after January 1, 2022 and is to be applied retrospectively, with earlier application permitted. The Company is still considering whether the new standard will have a significant impact on the consolidated financial statements.

Significant accounting polici_3

Significant accounting policies (Tables)	12 Months Ended
	Mar. 31, 2021
Disclosure Of Significant Accounting Policies [Abstract]
Disclosure of detailed information about subsidiaries [Table Text Block]	Place of incorporation Interest % Principal activity Burcon NutraScience (MB) Corp. Manitoba, Canada 100 Research and development Burcon NutraScience Holdings Corp. Canadian federally incorporated 100 Investment holding
Disclosure of detailed information about estimated useful life or depreciation rate [Table Text Block]	Equipment 20% declining balance Computer equipment 30% declining balance Leasehold improvements Straight-line over lease term Right-of-use assets Straight-line over lease term

Property and equipment (Tables)

Property and equipment (Tables)	12 Months Ended
	Mar. 31, 2021
Property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment [Table Text Block]	Right-of-Use Computer Leasehold Equipment Assets Equipment improvements Total $ $ $ $ $ Cost at March 31, 2019 3,777,382 — 85,662 — 3,863,044 Additions 241,683 — 19,218 — 260,901 Disposals — — (3,764 ) — (3,764 ) Cost at March 31, 2020 4,019,065 — 101,116 — 4,120,181 Accumulated amortization at March 31, 2019 3,501,562 — 76,793 — 3,578,355 Amortization 68,916 — 5,221 — 74,137 Disposal — — (2,815 ) — (2,815 ) Accumulated amortization at March 31, 2020 3,570,478 — 79,199 — 3,649,677 Net book value at March 31, 2020 448,587 — 21,917 — 470,504 Right-of-Use Computer Leasehold Equipment Assets Equipment improvements Total $ $ $ $ $ Cost at March 31, 2020 4,019,065 — 101,116 — 4,120,181 Additions 628,493 68,549 22,224 88,644 807,910 Cost at March 31, 2021 4,647,558 68,549 123,340 88,644 4,928,091 Accumulated amortization at March 31, 2020 3,570,478 — 79,199 — 3,649,677 Amortization 157,593 46,056 9,909 59,096 272,654 Accumulated amortization at March 31, 2021 3,728,071 46,056 89,108 59,096 3,922,331 Net book value at March 31, 2021 919,487 22,493 34,232 29,548 1,005,760

Deferred development costs (Tab

Deferred development costs (Tables)	12 Months Ended
	Mar. 31, 2021
Deferred Development Costs [Abstract]
Disclosure of detailed information about deferred development costs [Table Text Block]	$ Cost at March 31, 2020 1,554,584 Additions 2,909,164 Cost at March 31, 2021 4,463,748 Amortization and impairment at March 31, 2021 — Net book value at March 31, 2021 4,463,748 Cost at March 31, 2019 — Additions 1,554,584 Cost at March 31, 2020 1,554,584 Amortization and impairment at March 31, 2020 — Net book value at March 31, 2020 1,554,584

Investment in and loan to Mer_2

Investment in and loan to Merit Functional Foods Corporation (Tables)	12 Months Ended
	Mar. 31, 2021
Investment In And Loan To Shareholders [Abstract]
Disclosure of financial position of the subsidiary [Table Text Block]	As at March As at March 31, $ $ Current assets 16,125,384 5,828,739 Non-current assets 124,970,303 36,056,689 Current liabilities 9,303,585 11,369,931 Non-current liabilities 93,642,063 6,653,724
Disclosure of financial results of subsidiary [Table Text Block]	Year ended Period ended 1 $ $ Total revenue 396,093 — Loss for the year/period (6,837,195 ) (2,349,515 )
Disclosure of capital loan advances to subsidiary [Table Text Block]	Investment in $ Capital $ Loan receivable $ Total net $ At inception 1 — 11,000,000 11,000,001 Modification to loan terms 8,871,512 (8,871,512 ) — Capital loan advance — 1,613,002 386,998 2,000,000 Share of loss in Merit Foods — (939,806 ) — (939,806 ) Interest accretion — — 144,343 144,343 Net Investment in Merit Foods, March 31, 2020 1 9,544,708 2,659,829 12,204,538 Share of loss in Merit Foods — (2,421,459 ) — (2,421,459 ) Dilution gain of investment in Merit Foods — 6,384,942 — 6,384,942 Interest accretion — — 307,875 307,875 Expected credit loss provision — — (74,193 ) (74,193 ) Net Investment in Merit Foods, March 31, 2021 1 13,508,191 2,893,511 16,401,703

Shareholders' equity (Tables)

Shareholders' equity (Tables)	12 Months Ended
	Mar. 31, 2021
Equity [abstract]
Disclosure of number and weighted average exercise prices of share options [Table Text Block]	2021 2020 Number of Weighted $ Number of Weighted $ Outstanding - Beginning of year 4,507,606 3.32 3,953,739 3.46 Granted 1,253,000 3.95 757,000 1.88 Exercised (94,000 ) 0.56 (173,000 ) 0.41 Expired (717,500 ) 9.51 — — Cancelled — — (30,133 ) 1.96 Outstanding - End of year 4,949,106 2.63 4,507,606 3.32
Disclosure of range of exercise prices of outstanding share options [Table Text Block]	Options outstanding Options exercisable Range of Number outstanding at March 31, 2021 Weighted average remaining contractual (years) Weighted average exercise price $ Number exercisable at March 31, 2021 Weighted average exercise price $ 0.23 - 0.69 832,333 7.50 0.39 672,666 0.43 1.88 - 4.73 4,016,773 5.80 2.98 2,930,770 2.83 6.78 - 8.05 100,000 0.57 7.54 100,000 7.54 4,949,106 5.98 2.63 3,703,436 2.52
Disclosure of detailed information about options, valuation assumptions [Table Text Block]	2021 2020 Dividend yield 0.0% 0.0% Expected volatility 78.5 75.1 Risk-free interest rate 0.5 1.3% Expected forfeitures 7.2% 7.7 Expected average option term (years) 6.7 7.9

Research and development (Table

Research and development (Tables)	12 Months Ended
	Mar. 31, 2021
Disclosure Of Research And Development Expense [Abstract]
Disclosure of detailed information about research and development expense [Table Text Block]	2021 $ 2020 $ Salaries and benefits (note 9) 1,602,709 1,317,920 Laboratory operation 305,135 290,336 Amortization of property and equipment 225,180 72,187 Rent 108,346 87,720 Analyses and testing 62,874 55,740 Travel and meals — 16,554 Gross research and development expenses 2,304,244 1,840,457 Allocated to deferred development costs (1,163,856 ) (655,132 ) Allocated to inventory production (726,383 ) (463,474 ) Net research and development expenses 414,005 721,851

General and administrative (Tab

General and administrative (Tables)	12 Months Ended
	Mar. 31, 2021
Selling, general and administrative expense [abstract]
Disclosure of detailed information about general and administrative expense [Table Text Block]	2021 $ 2020 $ Salaries and benefits (note 9) 2,635,873 1,350,824 Professional fees 465,226 274,356 Investor relations 247,735 131,646 Office supplies and services (note 13) 170,494 165,050 Transfer agent and filing fees 57,030 27,289 Amortization 47,474 1,949 Financing expense (notes 5 and 13) 23,790 88,920 Other 6,272 3,788 Travel and meals 248 66,225 Rent — 76,226 3,654,142 2,186,273

Basic and diluted loss per sh_2

Basic and diluted loss per share (Tables)	12 Months Ended
	Mar. 31, 2021
Basic and diluted earnings per share [abstract]
Disclosure of detailed information about basic and diluted loss per share [Table Text Block]	2021 $ 2020 $ Loss for the year, being loss attributable to common shareholders - basic and diluted (617,492 ) (4,633,494 ) Weighted average common shares - basic and diluted 102,890,726 78,935,751 Basic and diluted loss per share (0.01 ) (0.06 )

Key management compensation (Ta

Key management compensation (Tables)	12 Months Ended
	Mar. 31, 2021
Disclosure Of Key Management Compensation [Abstract]
Disclosure of detailed information about remuneration of directors and key management personnel [Table Text Block]	2021 $ 2020 $ Short-term benefits 491,012 387,822 Option-based awards 1,367,502 372,223 1,858,514 760,045

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Major components of tax expense (income) [abstract]
Disclosure of detailed information about effective income tax expense (recovery) [Table Text Block]	2021 $ 2020 $ Recovery of income taxes based on the combined statutory income tax rate of 27.0% (2020 - 27.0%) (167,000 ) (1,251,000 ) Changes in unrecognized deferred tax assets (414,000 ) 1,384,000 Financing costs (1,000 ) (316,000 ) Non-deductible items and tax adjustments 582,000 183,000 Recovery of income taxes — —
Disclosure of detailed information about non-capital losses available [Table Text Block]	$ 2026 800,000 2027 1,124,000 2028 1,344,000 2029 1,596,000 2030 2,691,000 2031 4,358,000 2032 5,327,000 2033 4,606,000 2034 5,507,000 2035 5,623,000 2036 4,895,000 2037 4,612,000 2038 5,303,000 2039 5,215,000 2040 4,472,000 2041 5,282,000 62,755,000
Disclosure of detailed information about deferred taxes [Table Text Block]	2021 $ 2020 $ Deferred income tax assets (liability) SR&ED expenditures 4,073,000 4,073,000 Losses from operations carried forward 16,943,000 15,668,000 Investment in Merit Foods (918,000 ) 215,000 Deferred development costs (962,000 ) (386,000 ) Interest expense — (2,000 ) Financing costs 245,000 334,000 Property and equipment 245,000 132,000 Right-of-Use assets/liability (5,000 ) — Unrecognized deferred income tax assets 19,621,000 20,034,000

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
	Mar. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Disclosure of carrying values and fair values of financial instruments, by class [Table Text Block]	As at March 31, 2021 At fair value Financial Financial Fair value Financial assets $ $ $ $ Cash and cash equivalents — 13,972,659 — 13,972,659 Amounts receivable — 338,715 — 338,715 Loan to Merit Foods — 2,893,511 — 2,967,704 Total — 17,204,885 — 17,279,078 Financial liabilities Accounts payable and accrued liabilities — — 1,418,049 1,418,049 Total — — 1,418,049 1,418,049 As at March 31, 2020 At fair value Financial Financial Fair value Financial assets $ $ $ $ Cash and cash equivalents — 15,030,988 — 15,030,988 Amounts receivable — 332,248 — 332,248 Loan to Merit Foods — 2,659,830 — 2,659,830 Total — 18,023,066 — 18,023,066 Financial liabilities Accounts payable and accrued liabilities — — 1,067,251 1,067,251 Accrued interest — — 249,310 249,310 Convertible debentures — — 6,731,350 6,731,350 Total — — 8,047,911 8,047,911
Disclosure of detailed information about currency risk [Table Text Block]	March 31, March 31, U.S. Dollars Cash and cash equivalents $ 27,752 $ 21,819 Amounts receivable 1,851 2,528 Accounts payable and accrued liabilities — (40,556 ) Net exposure $ 29,603 $ (16,209 ) Canadian dollar equivalent $ 37,226 $ (22,996 )

Significant accounting polici_4

Significant accounting policies - Disclosure of detailed information about subsidiaries (Details)	12 Months Ended
	Mar. 31, 2021
Burcon NutraScience (MB) Corp. [Member]
Disclosure Of Significant Accounting Policies [Line Items]
Place of incorporation	Manitoba, Canada
Interest	100.00%
Burcon Nutrascience Holdings Corp [Member]
Disclosure Of Significant Accounting Policies [Line Items]
Place of incorporation	Canadian federally incorporated
Interest	100.00%

Significant accounting polici_5

Significant accounting policies - Disclosure of detailed information about estimated useful life or depreciation rate (Details)	12 Months Ended
	Mar. 31, 2021
Equipment [Member]
Disclosure Of Significant Accounting Policies [Line Items]
Description of useful life, property, plant and equipment	20% declining balance
Computer equipment [Member]
Disclosure Of Significant Accounting Policies [Line Items]
Description of useful life, property, plant and equipment	30% declining balance
Leasehold improvements [Member]
Disclosure Of Significant Accounting Policies [Line Items]
Description of useful life, property, plant and equipment	Straight-line over lease term
Right-of-use assets [Member]
Disclosure Of Significant Accounting Policies [Line Items]
Description of useful life, property, plant and equipment	Straight-line over lease term

Property and equipment (Narrati

Property and equipment (Narrative) (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, plant and equipment [abstract]
Cash grant received from government of Manitoba	$ 50,000	$ 0

Property and equipment - Disclo

Property and equipment - Disclosure of detailed information about property, plant and equipment (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	$ 470,504
Ending balance	1,005,760	$ 470,504
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	4,120,181	3,863,044
Additions	807,910	260,901
Disposal		(3,764)
Ending balance	4,928,091	4,120,181
Accumulated amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	3,649,677	3,578,355
Amortization	272,654	74,137
Disposal		(2,815)
Ending balance	3,922,331	3,649,677
Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance		448,587
Ending balance	919,487
Equipment [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	4,019,065	3,777,382
Additions	628,493	241,683
Disposal		0
Ending balance	4,647,558	4,019,065
Equipment [Member] | Accumulated amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	3,570,478	3,501,562
Amortization	157,593	68,916
Disposal		0
Ending balance	3,728,071	3,570,478
Right-of-use assets [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Ending balance	22,493	0
Right-of-use assets [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Additions	68,549	0
Disposal		0
Ending balance	68,549	0
Right-of-use assets [Member] | Accumulated amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Amortization	46,056	0
Disposal		0
Ending balance	46,056	0
Computer equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	21,917
Ending balance	34,232	21,917
Computer equipment [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	101,116	85,662
Additions	22,224	19,218
Disposal		(3,764)
Ending balance	123,340	101,116
Computer equipment [Member] | Accumulated amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	79,199	76,793
Amortization	9,909	5,221
Disposal		(2,815)
Ending balance	89,108	79,199
Leasehold improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0
Ending balance	29,548	0
Leasehold improvements [Member] | Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Additions	88,644	0
Disposal		0
Ending balance	88,644	0
Leasehold improvements [Member] | Accumulated amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0	0
Amortization	59,096	0
Disposal		0
Ending balance	$ 59,096	$ 0

Deferred development costs - Di

Deferred development costs - Disclosure of detailed information about deferred development costs (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Opening balance	$ 1,554,584
Amortization and impairment
Ending balance	4,463,748	1,554,584
Cost [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Opening balance	1,554,584	0
Additions	2,909,164	1,554,584
Ending balance	4,463,748	1,554,584
Accumulated amortization [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Amortization and impairment

Investment in and loan to Mer_3

Investment in and loan to Merit Functional Foods Corporation (Narrative) (Details) - CAD ($)	1 Months Ended				11 Months Ended	12 Months Ended
	Aug. 27, 2020	Jun. 30, 2020	May 31, 2020	May 23, 2019	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Investment In And Loan To Shareholders [Line Items]
Dilution gain of investment in Merit Foods						$ 6,384,942	$ 0
Expected credit loss provision						74,193
Merit Functional Foods Corporation [Member]
Investment In And Loan To Shareholders [Line Items]
Dilution gain of investment in Merit Foods						$ 6,384,942
Secured additional debt financing		$ 10,000,000
Term of loan		10-year				15 years
Interest rate on loan receivable						11.00%
Interest accretion					$ 144,343	$ 307,875
Expected credit loss provision						74,193
Management fee income						334,760	350,014
Sale of samples						524,321	114,766
Amounts receivable					$ 110,594	66,709	110,594
Professional fees expense						10,720
Financing package from Government of Canada						99,200,000
Total investment into the project						7,900,000
Merit Functional Foods Corporation [Member] | Burcon Holdings [Member]
Investment In And Loan To Shareholders [Line Items]
Proportion of ownership interest	33.30%			40.00%
Right to buy out amended license agreement						67,500,000
Merit Functional Foods Corporation [Member] | Other parties - one [Member]
Investment In And Loan To Shareholders [Line Items]
Proportion of ownership interests held by non-controlling interests				40.00%
Merit Functional Foods Corporation [Member] | Other parties - two [Member]
Investment In And Loan To Shareholders [Line Items]
Proportion of ownership interests held by non-controlling interests				20.00%
Merit Functional Foods Corporation [Member] | Each shareholder [Member]
Investment In And Loan To Shareholders [Line Items]
Capital loan advances						32,500,000
Merit Functional Foods Corporation [Member] | Bunge Limited [Member]
Investment In And Loan To Shareholders [Line Items]
Proportion of ownership interest	25.00%
Capital loan advances	$ 30,000,000
Merit Functional Foods Corporation [Member] | Loan Agreement [Member]
Investment In And Loan To Shareholders [Line Items]
Interest income						120,205
Interest income outstanding
Loan amount						6,500,000
Merit Functional Foods Corporation [Member] | Loan Agreement [Member] | Burcon Holdings [Member]
Investment In And Loan To Shareholders [Line Items]
Capital loan advances						$ 13,000,000
Merit Functional Foods Corporation [Member] | Subsequent events [Member]
Investment In And Loan To Shareholders [Line Items]
Amount of debt financing package from syndicate of lenders			$ 85,000,000
Letter of credit			6,500,000
Loan amount			$ 6,500,000
Interest rate on loan			5.00%
Maximum liability under guarantees			$ 4,000,000

Investment in and loan to Mer_4

Investment in and loan to Merit Functional Foods Corporation - Disclosure of financial position of the subsidiary (Details) - CAD ($)	Mar. 31, 2021	Mar. 31, 2020
Investment In And Loan To Shareholders [Line Items]
Current assets	$ 14,598,604	$ 15,784,656
Current liabilities	1,446,480	1,592,139
Merit Functional Foods Corporation [Member]
Investment In And Loan To Shareholders [Line Items]
Current assets	16,125,384	5,828,739
Non-current assets	124,970,303	36,056,689
Current liabilities	9,303,585	11,369,931
Non-current liabilities	$ 93,642,063	$ 6,653,724

Investment in and loan to Mer_5

Investment in and loan to Merit Functional Foods Corporation - Disclosure of financial results of subsidiary (Details) - CAD ($)	11 Months Ended	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Investment In And Loan To Shareholders [Line Items]
Total revenue		$ 258,646	$ 31,134
Loss for the year/period		(617,492)	$ (4,633,494)
Merit Functional Foods Corporation [Member]
Investment In And Loan To Shareholders [Line Items]
Total revenue	$ 0	396,093
Loss for the year/period	$ (2,349,515)	$ (6,837,195)

Investment in and loan to Mer_6

Investment in and loan to Merit Functional Foods Corporation - Disclosure of capital loan advances to subsidiary (Details) - CAD ($)	11 Months Ended	12 Months Ended
	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Investment In And Loan To Shareholders [Line Items]
Net Investment in Merit Foods, beginning balance		$ 12,204,538
Share of loss in Merit Foods		(2,421,459)	$ (939,806)
Dilution gain of investment in Merit Foods		6,384,942	0
Expected credit loss provision		(74,193)
Net Investment in Merit Foods, ending balance	$ 12,204,538	16,401,703	12,204,538
Merit Functional Foods Corporation [Member]
Investment In And Loan To Shareholders [Line Items]
Net Investment in Merit Foods, beginning balance	11,000,001	12,204,538
Modification to loan terms	0
Capital loan advance	2,000,000
Share of loss in Merit Foods	(939,806)	(2,421,459)
Dilution gain of investment in Merit Foods		6,384,942
Interest accretion	144,343	307,875
Expected credit loss provision		(74,193)
Net Investment in Merit Foods, ending balance	12,204,538	16,401,703	12,204,538
Merit Functional Foods Corporation [Member] | Investment in share capital [Member]
Investment In And Loan To Shareholders [Line Items]
Net Investment in Merit Foods, beginning balance	1	1
Capital loan advance	0
Share of loss in Merit Foods	0	0
Dilution gain of investment in Merit Foods		0
Interest accretion	0	0
Expected credit loss provision		0
Net Investment in Merit Foods, ending balance	1		1
Merit Functional Foods Corporation [Member] | Capital Contribution [Member]
Investment In And Loan To Shareholders [Line Items]
Net Investment in Merit Foods, beginning balance	0	9,544,708
Modification to loan terms	8,871,512
Capital loan advance	1,613,002
Share of loss in Merit Foods	(939,806)	(2,421,459)
Dilution gain of investment in Merit Foods		6,384,942
Interest accretion	0	0
Expected credit loss provision		0
Net Investment in Merit Foods, ending balance	9,544,708	13,508,191	9,544,708
Merit Functional Foods Corporation [Member] | Loan receivable [Member]
Investment In And Loan To Shareholders [Line Items]
Net Investment in Merit Foods, beginning balance	11,000,000	2,659,829
Modification to loan terms	(8,871,512)
Capital loan advance	386,998
Share of loss in Merit Foods	0	0
Dilution gain of investment in Merit Foods		0
Interest accretion	144,343	307,875
Expected credit loss provision		(74,193)
Net Investment in Merit Foods, ending balance	$ 2,659,829	$ 2,893,511	$ 2,659,829

Deferred revenue (Narrative) (D

Deferred revenue (Narrative) (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure Of Deferred Revenue [Abstract]
Research income	$ 250,000	$ 0

Convertible debentures and co_2

Convertible debentures and convertible note (Narrative) (Details) - CAD ($)	Sep. 08, 2020	Dec. 10, 2019	Apr. 07, 2016	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of detailed information about borrowings [line items]
Notes and debentures issued				$ 0	$ 2,762,927
Value of the conversion option					2,762,927
Convertible debentures [Member]
Disclosure of detailed information about borrowings [line items]
Notes and debentures issued		$ 9,500,000
Principal amount of each debenture		$ 1,000
Borrowings, interest rate		8.50%
Description of forceable conversion		Burcon had the right, at its sole discretion, to force the conversion of the Debentures if the shares traded at or above $2.15 for a period of 14 consecutive trading days.
Borrowing costs incurred		$ 228,432
Finder's fees		$ 156,600
Percentage of finders fees on total gross proceeds received		4.50%
Principal amount of convertible debt	$ 7,795,500	$ 1,704,500
Convertible debt conversion price		$ 1.05
Issuance of common shares	7,424,274	1,623,327
Future cash flow discount rate		24.00%
Fair value of debt		$ 6,508,641
Value of the conversion option		2,762,927
Interest expense on debt instruments issued				637,522
Convertible debentures [Member] | Directors and officers [Member]
Disclosure of detailed information about borrowings [line items]
Notes and debentures issued		$ 2,000,000
Convertible note [Member]
Disclosure of detailed information about borrowings [line items]
Notes and debentures issued			$ 2,000,000
Borrowings, interest rate			8.00%
Amount offset, including principal amount and accrued interest				$ 2,565,022
Expected volatility			63.00%			99.00%
Expected dividend convertible note			$ 0			$ 0
Risk-free interest rate			0.60%			1.63%
Expected average option term			3 years			1.1 years
Derivative liability			$ 189,705			$ 5,384

Short-term loan (Narrative) (De

Short-term loan (Narrative) (Details) - Large Scale Investments Limited [Member] - CAD ($)	1 Months Ended		12 Months Ended
	Jun. 28, 2019	Jun. 25, 2019	Mar. 31, 2021
Disclosure of detailed information about borrowings [line items]
Maximum principal amount available under Loan			$ 1,500,000
Borrowings, interest rate basis			The Loan bore interest at 18% per annum on the amount drawn, and 3% per annum on the undrawn portion.
Loan amount offset		$ 1,436,629
Repayment of principal amount	$ 63,371
Accrued interest	$ 107,173

Shareholders' equity (Narrative

Shareholders' equity (Narrative) (Details)	1 Months Ended			12 Months Ended
	Feb. 19, 2020CAD ($)$ / sharesshares	Jun. 28, 2019CAD ($)	Jun. 25, 2019CAD ($)Share$ / sharesshares	Mar. 31, 2021CAD ($)Share$ / sharesshares	Mar. 31, 2020CAD ($)Share$ / sharesshares	Mar. 31, 2019Share
Disclosure of classes of share capital [line items]
Net proceeds from issuing shares				$ 5,025,608	$ 25,752,074
Payments for share issue costs				$ 239,589	$ 1,381,417
Number of share options outstanding | Share				4,949,106	4,507,606	3,953,739
Weighted average exercise price of share options exercisable | $ / shares				$ 2.52
Additional options authorized under plan | shares				5,894,031	5,172,357
Term of share option granted				10 years
Weighted average fair value | $ / shares				$ 2.73	$ 1.36
Large Scale Investments Limited [Member]
Disclosure of classes of share capital [line items]
Repayment of convertible note, loan and accrued interest		$ 63,371
2020 Equity Offering [Member]
Disclosure of classes of share capital [line items]
Number of units issued | shares	7,419,800
Units issued, price per unit | $ / shares	$ 1.55
Gross proceeds from issuing units	$ 11,500,000
Net proceeds from issuing units	$ 10,300,000
Exercise price of warrants granted | $ / shares	$ 2
Estimated fair value of warrants granted	$ 1,780,752
Number of warrants exercised | shares				2,285,500
Proceeds from exercise of warrants				$ 4,571,000
Number of warrants outstanding | shares				1,424,400
Payments for share issue costs	$ 1,200,000
Agents’ warrants [Member]
Disclosure of classes of share capital [line items]
Percentage of cash commission on gross proceeds and compensation	7.00%
Number of warrants granted | shares	519,386
Exercise price of warrants granted | $ / shares	$ 2
Estimated fair value of warrants granted	$ 249,305
Number of warrants exercised | shares				207,754
Proceeds from exercise of warrants				$ 415,508
Number of warrants outstanding | shares				311,632
2019 Rights Offering [Member]
Disclosure of classes of share capital [line items]
Number of common shares in rights offering | shares			44,083,203
Price per common share issued | $ / shares			$ 0.35
Gross proceeds from issuing shares			$ 15,429,121
Net proceeds from issuing shares			$ 15,284,430
Per share price of right to purchase common share | $ / shares			$ 0.35
2019 Rights Offering [Member] | Directors and officers [Member]
Disclosure of classes of share capital [line items]
Rights exercised | Share			14,306,740
Percentage of Rights Offering shares issued as a result of Rights exercised			32.50%
2019 Rights Offering [Member] | Large Scale Investments Limited [Member] | Convertible note [Member]
Disclosure of classes of share capital [line items]
Repayment of convertible note, loan and accrued interest			$ 2,565,022
2019 Rights Offering [Member] | Large Scale Investments Limited [Member] | Loan [Member]
Disclosure of classes of share capital [line items]
Repayment of convertible note, loan and accrued interest			$ 1,607,183
Bottom of range [Member]
Disclosure of classes of share capital [line items]
Weighted average exercise price of share options exercisable | $ / shares				$ 0.23
Top of range [Member]
Disclosure of classes of share capital [line items]
Weighted average exercise price of share options exercisable | $ / shares				$ 8.05
Research and development [Member]
Disclosure of classes of share capital [line items]
Stock-based compensation				$ 7,706	$ 16,757
General and administrative [Member]
Disclosure of classes of share capital [line items]
Stock-based compensation				1,550,828	469,472
Deferred development costs [Member]
Disclosure of classes of share capital [line items]
Stock-based compensation				$ 319,610	$ 50,660

Shareholders' equity - Disclosu

Shareholders' equity - Disclosure of number and weighted average exercise prices of share options (Details)	12 Months Ended
	Mar. 31, 2021Share$ / shares	Mar. 31, 2020Share$ / shares
Equity [abstract]
Number of share options outstanding at beginning of year | Share	4,507,606	3,953,739
Weighted average exercise price of share options outstanding at beginning of year | $ / shares	$ 3.32	$ 3.46
Number of share options granted | Share	1,253,000	757,000
Weighted average exercise price of share options granted | $ / shares	$ 3.95	$ 1.88
Number of share options exercised | Share	(94,000)	(173,000)
Weighted average exercise price of share options exercised | $ / shares	$ 0.56	$ 0.41
Number of share options expired | Share	(717,500)	0
Weighted average exercise price of share options expired | $ / shares	$ 9.51	$ 0
Number of share options cancelled | Share	0	(30,133)
Weighted average exercise price of share options cancelled | $ / shares	$ 0	$ 1.96
Number of share options outstanding at end of year | Share	4,949,106	4,507,606
Weighted average exercise price of share options outstanding at end of year | $ / shares	$ 2.63	$ 3.32

Shareholders' equity - Disclo_2

Shareholders' equity - Disclosure of range of exercise prices of outstanding share options (Details)	12 Months Ended
	Mar. 31, 2021Share$ / shares	Mar. 31, 2020Share$ / shares	Mar. 31, 2019Share$ / shares
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of share options outstanding in share-based payment arrangement | Share	4,949,106	4,507,606	3,953,739
Weighted average remaining contractual life of outstanding share options	5 years 11 months 23 days
Weighted average exercise price of share options outstanding in share-based payment arrangement	$ 2.63	$ 3.32	$ 3.46
Number of share options exercisable in share-based payment arrangement | Share	3,703,436
Weighted average exercise price of share options exercisable in share-based payment arrangement	$ 2.52
Range of exercise prices $ 0.23 - 0.69 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of share options outstanding in share-based payment arrangement | Share	832,333
Weighted average remaining contractual life of outstanding share options	7 years 6 months
Weighted average exercise price of share options outstanding in share-based payment arrangement	$ 0.39
Number of share options exercisable in share-based payment arrangement | Share	672,666
Weighted average exercise price of share options exercisable in share-based payment arrangement	$ 0.43
Range of exercise prices $ 0.23 - 0.69 [Member] | Minimum [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price of outstanding share options	0.23
Range of exercise prices $ 0.23 - 0.69 [Member] | Maximum [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price of outstanding share options	$ 0.69
Range of exercise prices $ 1.88 - 4.73 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of share options outstanding in share-based payment arrangement | Share	4,016,773
Weighted average remaining contractual life of outstanding share options	5 years 9 months 18 days
Weighted average exercise price of share options outstanding in share-based payment arrangement	$ 2.98
Number of share options exercisable in share-based payment arrangement | Share	2,930,770
Weighted average exercise price of share options exercisable in share-based payment arrangement	$ 2.83
Range of exercise prices $ 1.88 - 4.73 [Member] | Minimum [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price of outstanding share options	1.88
Range of exercise prices $ 1.88 - 4.73 [Member] | Maximum [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price of outstanding share options	$ 4.73
Range of exercise prices $ 6.78 - 8.05 [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number of share options outstanding in share-based payment arrangement | Share	100,000
Weighted average remaining contractual life of outstanding share options	6 months 25 days
Weighted average exercise price of share options outstanding in share-based payment arrangement	$ 7.54
Number of share options exercisable in share-based payment arrangement | Share	100,000
Weighted average exercise price of share options exercisable in share-based payment arrangement	$ 7.54
Range of exercise prices $ 6.78 - 8.05 [Member] | Minimum [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price of outstanding share options	6.78
Range of exercise prices $ 6.78 - 8.05 [Member] | Maximum [Member]
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Exercise price of outstanding share options	$ 8.05

Shareholders' equity - Disclo_3

Shareholders' equity - Disclosure of detailed information about options, valuation assumptions (Details) - years	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Equity [abstract]
Dividend yield	0.00%	0.00%
Expected volatility	78.50%	75.10%
Risk-free interest rate	0.50%	1.30%
Expected forfeitures	7.20%	7.70%
Expected average option term (years)	6.7	7.9

Research and development (Narra

Research and development (Narrative) (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Canada Emergency Wage Subsidy ("CEWS") and Canada Emergency Rent Subsidy programs ("CERS") [Member]
Research And Development [Line Items]
Subsidies reducing research and development expense	$ 115,013	$ 0
Manitoba Government [Member]
Research And Development [Line Items]
Training grant	$ 45,099	$ 21,529

Research and development - Disc

Research and development - Disclosure of detailed information about research and development expense (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Research And Development [Line Items]
Net research and development expenses	$ 414,005	$ 721,851
Research and development [Member]
Research And Development [Line Items]
Salaries and benefits	1,602,709	1,317,920
Laboratory operation	305,135	290,336
Amortization of property and equipment	225,180	72,187
Rent	108,346	87,720
Analyses and testing	62,874	55,740
Travel and meals	0	16,554
Gross research and development expenses	2,304,244	1,840,457
Allocated to deferred development costs	(1,163,856)	(655,132)
Allocated to inventory production	(726,383)	(463,474)
Net research and development expenses	$ 414,005	$ 721,851

General and administrative (Nar

General and administrative (Narrative) (Details)	12 Months Ended
	Mar. 31, 2021CAD ($)
Canada Emergency Wage Subsidy [Member]
Disclosure Of Government Subsidy [Line Items]
Subsidies reducing salaries and benefits	$ 145,765

General and administrative - Di

General and administrative - Disclosure of detailed information about general and administrative expenses (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
General And Administrative [Line Items]
Total general and administrative	$ 3,654,142	$ 2,186,273
General and administrative [Member]
General And Administrative [Line Items]
Salaries and benefits	2,635,873	1,350,824
Professional fees	465,226	274,356
Investor relations	247,735	131,646
Office supplies and services	170,494	165,050
Transfer agent and filing fees	57,030	27,289
Amortization	47,474	1,949
Financing expense	23,790	88,920
Other	6,272	3,788
Travel and meals	248	66,225
Rent	0	76,226
Total general and administrative	$ 3,654,142	$ 2,186,273

Basic and diluted loss per sh_3

Basic and diluted loss per share - Disclosure of detailed information about basic and diluted loss per share (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Basic and diluted earnings per share [abstract]
Loss for the year, being loss attributable to common shareholders - basic and diluted	$ (617,492)	$ (4,633,494)
Weighted average common shares - basic and diluted	102,890,726	78,935,751
Basic and diluted loss per share	$ (0.01)	$ (0.06)

Related party transactions (Nar

Related party transactions (Narrative) (Details) - CAD ($)	1 Months Ended	12 Months Ended
	Jun. 28, 2019	Mar. 31, 2021	Mar. 31, 2020	Dec. 10, 2019	Apr. 07, 2016
Disclosure of transactions between related parties [line items]
Convertible debentures		$ 0	$ 2,762,927
Interest expense		770,404	589,277
Accrued interest		0	249,310
Convertible debentures [Member]
Disclosure of transactions between related parties [line items]
Convertible debentures				$ 9,500,000
Convertible note [Member]
Disclosure of transactions between related parties [line items]
Convertible debentures					$ 2,000,000
Officers [Member]
Disclosure of transactions between related parties [line items]
Office space rental		4,584	75,006
Management fee expense		2,241	1,181
Amounts payable, related party transactions		75	11
Management fee income		7,709	14,197
Amounts receivable, related party transactions		437	1,785
Directors and officers [Member] | Convertible debentures [Member]
Disclosure of transactions between related parties [line items]
Convertible debentures				$ 2,000,000
Interest payment		126,803
Large Scale [Member]
Disclosure of transactions between related parties [line items]
Interest payment	$ 107,173
Large Scale [Member] | Loan [Member]
Disclosure of transactions between related parties [line items]
Interest expense		60,756
Large Scale [Member] | Convertible note [Member]
Disclosure of transactions between related parties [line items]
Interest expense		56,502
Merit Functional Foods Corporation [Member]
Disclosure of transactions between related parties [line items]
Professional fees expense		10,720
Management fee income		334,760	350,014
Merit Functional Foods Corporation [Member] | Loan Agreement [Member]
Disclosure of transactions between related parties [line items]
Loan amount		6,500,000
Interest income		120,205
Interest receivable
2019 Rights Offering [Member] | Dr. Yap [Member]
Disclosure of transactions between related parties [line items]
Warrant valuation adjustment			$ 85,420
Number of warrants exercised			1,182,099
2019 Rights Offering [Member] | Dr. Yap [Member] | Top of range [Member]
Disclosure of transactions between related parties [line items]
Warrant or right exercise price of warrants issued			$ 0.69
2019 Rights Offering [Member] | Dr. Yap [Member] | Bottom of range [Member]
Disclosure of transactions between related parties [line items]
Warrant or right exercise price of warrants issued			$ 0.45

Key management compensation - D

Key management compensation - Disclosure of detailed information about remuneration of directors and key management personnel (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure Of Key Management Compensation [Abstract]
Short-term benefits	$ 491,012	$ 387,822
Option-based awards	1,367,502	372,223
Total key management compensation	$ 1,858,514	$ 760,045

Income taxes (Narrative) (Detai

Income taxes (Narrative) (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Refundable income tax credits recorded in interest and other income		$ 18,655
Refundable income tax credits recorded in interest and other income included in amounts receivable	18,655	18,655
Non-capital losses carried forward [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	62,755,000	$ 58,032,000
SR&ED expenditures [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Expenses that can be used to reduce income	15,130,000
Investment Tax Credits [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unused tax credits for which no deferred tax asset recognised	$ 5,032,000

Income taxes - Disclosure of de

Income taxes - Disclosure of detailed information about effective income tax expense (recovery) (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Major components of tax expense (income) [abstract]
Recovery of income taxes based on the combined statutory income tax rate	$ (167,000)	$ (1,251,000)
Statutory income tax rate	27.00%	27.00%
Changes in unrecognized deferred tax assets	$ (414,000)	$ 1,384,000
Financing costs	(1,000)	(316,000)
Non-deductible items and tax adjustments	582,000	183,000
Recovery of income taxes	$ 0	$ 0

Income taxes - Disclosure of _2

Income taxes - Disclosure of detailed information about non capital losses available (Details) - Non-capital losses carried forward [Member] - CAD ($)	Mar. 31, 2021	Mar. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	$ 62,755,000	$ 58,032,000
2026 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	800,000
2027 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	1,124,000
2028 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	1,344,000
2029 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	1,596,000
2030 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	2,691,000
2031 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	4,358,000
2032 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	5,327,000
2033 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	4,606,000
2034 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	5,507,000
2035 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	5,623,000
2036 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	4,895,000
2037 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	4,612,000
2038 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	5,303,000
2039 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	5,215,000
2040 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	4,472,000
2041 [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Non-capital losses	$ 5,282,000

Income taxes - Disclosure of _3

Income taxes - Disclosure of detailed information about deferred taxes (Details) - CAD ($)	Mar. 31, 2021	Mar. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	$ 19,621,000	$ 20,034,000
SR&ED expenditures [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	4,073,000	4,073,000
Losses from operations carried forward [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	16,943,000	15,668,000
Investment in Merit Foods [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	(918,000)	215,000
Deferred development costs [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	(962,000)	(386,000)
Interest expense [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	0	(2,000)
Financing costs [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	245,000	334,000
Property and equipment [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	245,000	132,000
Right-of-Use assets/liability [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Unrecognized deferred tax assets / liability	$ (5,000)	$ 0

Financial instruments (Narrativ

Financial instruments (Narrative) (Details) - CAD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of detailed information about financial instruments [abstract]
Expected credit loss provision	$ 74,193
Weighted average interest rate earned on cash and cash equivalents	0.36%	1.92%
Percentage of strengthening or weakening of interest rates on cash and cash equivalents	1.00%
Estimated increase or decrease in interest income per year due to potential fluctuations in interest rates	$ 140,000
Estimated minimum contractual undiscounted cash flow for financial liabilities	$ 1,418,049
Percentage of appreciation or depreciation of U.S. dollar against Canadian dollar	10.00%
Increase or decrease in loss from operations due to potential change in exchange rate	$ 3,000	$ 2,000

Financial instruments -Disclosu

Financial instruments -Disclosure of carrying values and fair values of financial instruments, by class (Details) - CAD ($)	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Financial assets
Cash and cash equivalents	$ 13,972,659	$ 15,030,988	$ 489,215
Amounts receivable	338,715	332,248
Financial liabilities
Accounts payable and accrued liabilities	1,418,049	1,067,251
Accrued interest	0	249,310
Deferred revenue	0	275,578
Convertible debentures	0	6,731,350
At fair value through profit or loss [Member]
Financial assets
Cash and cash equivalents	0	0
Amounts receivable	0	0
Loan to Merit Foods	0	0
Total	0	0
Financial liabilities
Accounts payable and accrued liabilities	0	0
Accrued interest		0
Convertible debentures		0
Total	0	0
Financial assets at amortised cost [Member]
Financial assets
Cash and cash equivalents	13,972,659	15,030,988
Amounts receivable	338,715	332,248
Loan to Merit Foods	2,893,511	2,659,830
Total	17,204,885	18,023,066
Financial liabilities
Accounts payable and accrued liabilities	0	0
Accrued interest		0
Convertible debentures		0
Total	0	0
Financial liabilities at amortised cost [Member]
Financial assets
Cash and cash equivalents	0	0
Amounts receivable	0	0
Loan to Merit Foods	0	0
Total	0	0
Financial liabilities
Accounts payable and accrued liabilities	1,418,049	1,067,251
Accrued interest		249,310
Convertible debentures		6,731,350
Total	1,418,049	8,047,911
Fair value [Member]
Financial assets
Cash and cash equivalents	13,972,659	15,030,988
Amounts receivable	338,715	332,248
Loan to Merit Foods	2,967,704	2,659,830
Total	17,279,078	18,023,066
Financial liabilities
Accounts payable and accrued liabilities	1,418,049	1,067,251
Accrued interest		249,310
Convertible debentures		6,731,350
Total	$ 1,418,049	$ 8,047,911

Financial instruments - Disclos

Financial instruments - Disclosure of detailed information about currency risk (Details) - CAD ($)	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 13,972,659	$ 15,030,988	$ 489,215
Amounts receivable	338,715	332,248
Accounts payable and accrued liabilities	(1,418,049)	(1,067,251)
Currency risk [Member] | Denominated in U.S. dollars [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	27,752	21,819
Amounts receivable	1,851	2,528
Accounts payable and accrued liabilities	0	(40,556)
Net exposure	29,603	(16,209)
Currency risk [Member] | Canadian Dollar equivalent [Member]
Disclosure of detailed information about financial instruments [line items]
Net exposure	$ 37,226	$ (22,996)

Subsequent events (Narrative) (

Subsequent events (Narrative) (Details)	12 Months Ended
	Mar. 31, 2021CAD ($)Share$ / sharesshares	Mar. 31, 2020Share$ / shares
Disclosure of non-adjusting events after reporting period [line items]
Number of share options exercised | Share	94,000	173,000
Weighted average exercise price of share options exercised	$ 0.56	$ 0.41
Number of share options granted | Share	1,253,000	757,000
Weighted average exercise price of options granted	$ 3.95	$ 1.88
Subsequent events [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of warrants exercised | shares	45,750
Proceeds from exercise of warrants | $	$ 91,500
Number of share options exercised | $	12,300
Weighted average exercise price of share options exercised	$ 0.85
Subsequent events [Member] | Employees [Member]
Disclosure of non-adjusting events after reporting period [line items]
Number of share options granted | $	88,000
Weighted average exercise price of options granted	$ 4.89